



Title	Associations among maternal perfluoroalkyl substance levels, fetal sex-hormone enzymatic gene polymorphisms, and fetal sex hormone levels in the Hokkaido study
Author(s)	Kobayashi, Sumitaka; Sata, Fumihiko; Ikeda-Araki, Atsuko; Miyashita, Chihiro; Itoh, Sachiko; Goudarzi, Housman; Iwasaki, Yusuke; Mitsui, Takahiko; Moriya, Kimihiko; Shinohara, Nobuo; Cho, Kazutoshi; Kishi, Reiko
Citation	Reproductive toxicology, 105, 221-231 https://doi.org/10.1016/j.reprotox.2021.09.003
Issue Date	2021-10
Doc URL	http://hdl.handle.net/2115/87341
Rights	© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	http://creativecommons.org/licenses/by-nc-nd/4.0/
Type	article (author version)
File Information	4_Reprod Toxicol_2021.pdf



[Instructions for use](#)

1 Associations among maternal perfluoroalkyl substance levels, fetal sex-hormone enzymatic gene
2 polymorphisms, and fetal sex hormone levels in the Hokkaido study

3

4 Sumitaka Kobayashi^a, Fumihiro Sata^{a,b}, Atsuko Araki^a, Chihiro Miyashita^a, Sachiko Itoh^a,
5 Houman Goudarzi^{a,c}, Yusuke Iwasaki^d, Takahiko Mitsui^e, Kimihiko Moriya^f, Nobuo Shinohara^f,
6 Kazutoshi Cho^g, Reiko Kishi^{a,*}

7

8 ^a Center for Environmental and Health Sciences, Hokkaido University, North-12, West-7, Kita-
9 ku, Sapporo 060-0812, Japan

10 ^b Health Center, Chuo University, 42-8, Ichigaya-Hommura-cho, Shinjuku-ku, Tokyo 162-8473,
11 Japan

12 ^c Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine,
13 Hokkaido University, North-15, West-7, Kita-ku, Sapporo 060-8638, Japan

14 ^d Department of Biopharmaceutics and Analytical Science, Hoshi University, 2-4-41, Ebara,
15 Shinagawa-ku, Tokyo 142-8501, Japan

16 ^e Department of Urology, Interdisciplinary Graduate School of Medicine, University of
17 Yamanashi, 1110, Shimokato, Chuo 409-3898, Japan

18 ^f Department of Renal and Genitourinary Surgery, Faculty of Medicine and Graduate School of
19 Medicine, Hokkaido University, North-15, West-7, Kita-ku, Sapporo 060-8638, Japan

20 ^g Maternity and Perinatal Care Center, Hokkaido University Hospital, North-14, West-7, Kita-ku,
21 Sapporo 060-8648, Japan

22

23 *** Corresponding author**

24 Reiko Kishi, PhD, MD, MPH

25 Center for Environmental and Health Sciences, Hokkaido University, North-12, West-7, Kita-ku,
26 Sapporo 060-0812, Japan

1 E-mail: rkishi@med.hokudai.ac.jp

2 Tel: +81-(0)11-706-4746

3 Fax: +81-(0)11-706-4725

4

5 **Highlights**

- 6 ● Maternal perfluorooctanesulfonate levels associate with three sex hormone levels.
- 7 ● There are changes in progesterone, dehydroepiandrosterone, and estradiol levels.
- 8 ● Gene-perfluorooctanesulfonate interaction associates with sex hormone levels.
- 9 ● Only female infants show gene-perfluorooctanesulfonate interaction.
- 10 ● *Cytochrome P450 17A1* (rs743572) affects androstenedione and testosterone levels.

11

12 **Abstract**

13 Prenatal sex hormones affect fetal growth; for example, prenatal exposure to low levels of
14 androgen accelerates female puberty onset. We assessed the association of perfluoroalkyl
15 substances (PFASs) in maternal sera and infant genotypes of genes encoding enzymes involved
16 in sex steroid hormone biosynthesis on cord sera sex hormone levels in a prospective birth
17 cohort study of healthy pregnant Japanese women (n = 224) recruited in Sapporo between July
18 2002 and October 2005. We analyzed PFAS and five sex hormone levels using liquid
19 chromatography-tandem mass spectrometry. *Cytochrome P450 (CYP) 17A1 (CYP17A1*
20 *rs743572), 19A1 (CYP19A1 rs10046, rs700519, and rs727479), 3 β -hydroxysteroid*
21 *dehydrogenase type 1 (HSD3B1 rs6203), type 2 (HSD3B2 rs1819698, rs2854964, and*
22 *rs4659175), 17 β -hydroxysteroid dehydrogenase type 1 (HSD17B1 rs605059, rs676387, and*
23 *rs2676531), and type 3 (HSD17B3 rs4743709) were analyzed using real-time PCR. Multiple*
24 *linear regression models were used to establish the influence of log₁₀-transformed PFAS levels*
25 *and infant genotypes on log₁₀-transformed sex steroid hormone levels. When the interaction*
26 *between perfluorooctanesulfonate (PFOS) levels and female infant genotype CYP17A1*

1 (rs743572) on the androstenedione (A-dione) levels was considered, the estimated changes
2 (95% confidence intervals) in A-dione levels against PFOS levels, female infant genotype
3 *CYP17A1* (rs743572)-AG/GG, and interaction between them showed a mean increase of 0.445
4 (0.102, 0.787), mean increase of 0.392 (0.084, 0.707), and mean reduction of 0.579 (0.161,
5 0.997) ($P_{int} = 0.007$), respectively. Moreover, a female-specific interaction with testosterone
6 levels was observed. A-dione and T levels showed positive main effects and negative interaction
7 with PFOS levels and the female infant *CYP17A1* genotype.

8

9 **Keywords**

10 Perfluoroalkyl substances; Genotype; Cytochrome P450 17A1; Sex hormone; Gene-
11 environment interaction; Sex difference

12

13 **Abbreviations**

14 A-dione: Androstenedione; CI: Confidence interval; CYP: Cytochrome P450; *CYP17A1*:
15 Cytochrome P450 17A1; *CYP19A1*: Cytochrome P450 19A1; DHEA:
16 Dehydroepiandrosterone; E₂: Estradiol; HSD3B: 3 β -hydroxysteroid dehydrogenase; HSD3B1:
17 3 β -hydroxysteroid dehydrogenase type 1; HSD3B2: 3 β -hydroxysteroid dehydrogenase type 2;
18 HSD17B: 17 β -hydroxysteroid dehydrogenase; HSD17B1: 17 β -hydroxysteroid dehydrogenase
19 type 1; HSD17B3: 17 β -hydroxysteroid dehydrogenase type 3; HWE: Hardy-Weinberg
20 equilibrium; IQR: Inter-quartile range; LC/MS/MS: Liquid chromatography-tandem mass
21 spectrometry; LD: Linkage disequilibrium; LOD: Limit of detection; LOQ: Limits of
22 quantification; p_{int} : p for interaction; PFAS: Perfluoroalkyl substance; PFOA: Perfluorooctanoic
23 acid; PFOS: Perfluorooctanesulfonate; P₄: Progesterone; SD: Standard deviation; SNP: Single
24 nucleotide polymorphism; T: Testosterone

25

26

1 **1. Introduction**

2 Perfluoroalkyl substances (PFASs), such as perfluorooctanesulfonate (PFOS) and
3 perfluorooctanoic acid (PFOA), are poorly biodegradable compounds that persist and accumulate
4 in the environment. Increased PFOS levels during pregnancy are associated with decreased
5 dehydroepiandrosterone (DHEA) [1] and progesterone (P₄) [2] and increased estradiol (E₂) [2]
6 levels in cord blood. They are associated with increased testosterone (T) levels in offspring at 15
7 years [3], but not associated with T and DHEA levels in offspring up to 20 years [4]. Increased
8 PFOA levels were associated with increased DHEA levels in cord blood [1], luteinizing hormone
9 and follicle-stimulating hormone levels in offspring at 15 years [5], but they were not associated
10 with T and DHEA levels in female offspring up to 20 years [4]. Our previous study showed that
11 increased PFOS, but not PFOA, levels are associated with decreased birth weight [6]. Thus, it is
12 important to evaluate the effects of exposure to environmental chemicals on hormones as multiple
13 hormones affect biological functions, and maintaining their balance is important to health.

14 The human biosynthetic pathway of sex steroid hormones related to PFAS exposure during
15 pregnancy is shown in Fig. 1. Humans synthesize the male hormone T and the female hormone
16 E₂ from cholesterol via P₄, DHEA, and androstenedione (A-dione) [7]. The cytochrome P450
17 (CYP) 17A1 (*CYP17A1*) gene encodes the CYP17 enzyme that is associated with the early stages
18 of sex steroid hormone biosynthesis and catalyzes the conversion of pregnenolone and P₄ to
19 DHEA and A-dione, respectively [7]. *CYP19A1* encodes the CYP19 enzyme (aromatase), which
20 is associated with the final stage of sex steroid hormone biosynthesis and catalyzes the conversion
21 of androgenic steroids, particularly A-dione to estrone and T to E₂ [7]. The 3 β -hydroxysteroid
22 dehydrogenase (HSD3B) type 1 (*HSD3B1*) and type 2 (*HSD3B2*) genes encode the HSD3B
23 enzyme that is associated with the early stages of sex steroid hormone biosynthesis and catalyzes
24 the conversion of pregnenolone to P₄ and DHEA to A-dione [7], whereas the 17 β -hydroxysteroid
25 dehydrogenase (HSD17B) type 1 (*HSD17B1*) and type 3 (*HSD17B3*) genes encode the HSD17B
26 enzyme, which is associated with the final stages of sex steroid hormone biosynthesis and

1 catalyzes the conversion of A-dione to T and estrone to E₂ [7].

2 The genes regulating the biosynthesis of sex steroid hormones can affect the circulating sex
3 hormone levels [8,9] and may modulate the susceptibility to PFASs during fetal growth and
4 development. Previous studies have indicated that CYP directly metabolizes PFASs from the
5 PFASs precursors [10-12]. PFOS increases *CYP19* and *HSD3B2* transcription levels [13] and
6 *CYP17A1*, *HSD3B*, and *HSD17B* mRNA levels [14,15]. PFOA increases *CYP19* and *HSD3B2*
7 transcription levels [13]. Therefore, PFASs could directly affect the expression of these enzymes.
8 In this study, we focused on 12 single nucleotide polymorphisms (SNPs), which are well-known
9 disease-susceptibility genes encoding enzymes related to sex steroid hormone biosynthesis. The
10 SNPs of *CYP17A1* (A > G, dbSNP ID: rs743572) [16,17], *CYP19A1* (C > T; dbSNP ID: rs10046)
11 [18], *CYP19A1* (C > T; dbSNP ID: rs700519) [19,20], *CYP19A1* (A > C; dbSNP ID: rs727479)
12 [21], *HSD3B1* (T > C, Leu338Leu; rs6203) [22], *HSD17B1* (A > G, dbSNP ID: rs605059) [23],
13 *HSD17B1* (C > A, dbSNP ID: rs676387) [24], and *HSD17B3* (T > C, dbSNP ID: rs4743709) [20,25]
14 have been identified as genetic variants in genes associated with disease susceptibility. In addition,
15 *HSD3B2* (C > T, rs1819698) [26], *HSD3B2* (A > T, rs2854964) [26], and *HSD17B1* (C > T,
16 rs2676531) [27] have been linked to hypertensive disorder and familial amyloid polyneuropathy.
17 *HSD3B2* (C > T, rs4659175) has been associated with salivary T levels in girls with transferrin
18 levels of < 0.50 ng/dL according to a random forest analysis of genotypes with ± 5 kb of genes
19 participating in T synthesis, transport, signaling, and metabolism [28]. However, it is unclear
20 whether these genotypes in the fetus universally modify the associations between the PFAS levels
21 during pregnancy and the sex steroid hormone levels in cord blood. Fetal genetic factors may be
22 partially responsible for modifying the association between the PFAS and sex hormone levels.

23 Haplotypes, which refer to groups of genetic variants that tend to be inherited together, can
24 be used not only to track inheritance patterns but also for keeping the statistical power of a study.
25 Functional and informative structural gene patterns have been reported via therapeutic outcomes
26 and evolutionary analysis [29,30]. Haplotype surveys suggest that it is valuable to interpret

1 unknown or known functional genotypes in their functional, structural gene patterns, which may
2 help resolve the causal relationship regarding gene-environment interactions found across a wide
3 variety of epidemiological studies. In a specific population, a specific region on the genome with
4 almost no trace of genetic recombination is a haplotype block, and the linkage disequilibrium
5 (LD) of this block is very strong. Even if you do not know the haplotype frequency, you can
6 examine the haplotype block using LD analysis. A tag SNP refers to an SNP selected to identify
7 a combination of haplotypes existing in the same compartment. In particular, the utilization of tag
8 SNP by using the haplotype block instead of typing all the SNPs can improve the efficiency of
9 statistical analysis.

10 Many previous studies have investigated the association between environmental exposures
11 and sex hormones. However, the effect of genetic factors has not been investigated in these studies.
12 It is thought that heredity and environment influence each other on the sex hormone levels.
13 Therefore, we need to re-examine the relationship between environmental factors and sex
14 hormones while considering the genetic factors. In our previous studies, we have investigated the
15 association between maternal genotypes and prenatal chemical exposure due to various factors,
16 such as smoking, consumption of caffeine, and exposure to dioxins and PFASs on fetal growth
17 [31-35], and the association between the PFAS levels in the sera of pregnant Japanese women and
18 the sex steroid hormone (P₄, DHEA, A-dione, T, and E₂) levels in cord blood [1,2]. We
19 hypothesized that there might be specific genotypes of sex hormone biosynthesis genes and
20 increased exposure to PFASs results in sex-specific differences in the levels of sex hormones.
21 Following up on the studies conducted by Goudarzi et al. [1] and Itoh et al. [2], we used 12 SNP
22 tags (*CYP17A1* rs743572; *CYP19A1* rs10046, rs700519, and rs727479; *HSD3B1* rs6203;
23 *HSD3B2* rs1819698, rs2854964, and rs4659175; *HSD17B1* rs605059, rs676387, and rs2676531;
24 and *HSD17B3* rs4743709) encoding enzymes that are involved in sex steroid hormone
25 biosynthesis, and explored the association between PFAS levels during pregnancy in maternal
26 blood, infant genotypes, and sex hormone (P₄, DHEA, A-dione, DHEA/A-dione, T, and E₂, T/E₂)

1 levels in cord blood.

2

3 **2. Materials and methods**

4 **2.1. Study participants**

5 This prospective birth cohort study was based on the Hokkaido Study on Environment and
6 Children's Health (Sapporo cohort). The study protocol has been described previously [36-38].
7 Briefly, from July 2002 to October 2005, pregnant Japanese women ($n = 514$) were recruited from
8 a local obstetrics and gynecology hospital in Sapporo City. Of these, 10 participants withdrew. Of
9 the remaining 504, 224 participants provided complete data on PFOS and PFOA levels, infant
10 genotypes, and sex hormone levels (Fig. 2).

11

12 **2.2. Ethical approval**

13 Written informed consent was obtained from all the participants. All the procedures were
14 conducted in accordance with the Declaration of Helsinki, and the study protocol was approved
15 by the Institutional Ethical Board for Human Gene and Genome Studies and the Epidemiological
16 Studies Programs of the Hokkaido University Center for Environmental and Health Sciences
17 (approval number 119).

18

19 **2.3. Data collection**

20 Each participant completed a self-administered questionnaire at enrollment regarding maternal
21 age, annual household income, maternal smoking during the third trimester, and maternal alcohol
22 consumption during pregnancy. Medical records were also obtained to collect information on
23 parity and infant sex.

24

25 **2.4. Measurement of maternal serum PFOS and PFOA levels**

26 PFOS and PFOA levels were measured in 447 maternal blood samples. Those of the other

1 participants were not analyzed because they were either not available or the sample volume was
2 insufficient. Of the 447 blood samples, 228 were collected during pregnancy (mean \pm standard
3 deviation of gestational weeks at blood sample collection: 33.2 ± 3.7 weeks) and 159 were
4 obtained after delivery owing to anemia during pregnancy. Hence, we analyzed the 447 samples
5 for PFOS and PFOA levels using liquid chromatography-tandem mass spectrometry (LC/MS/MS),
6 according to the methods described previously [6,39]. All the samples surpassed the limit of
7 detection (LOD; 0.50 ng/mL) for PFOS. However, 16 (5.9%) samples had PFOA levels below
8 the LOD (0.50 ng/mL), and these cases were assigned a value of 0.25 ng/mL (50% of LOD).

9

10 **2.5. Assessment of infant genotype**

11 We evaluated the genotypes of *CYP17A1* (rs743572), *CYP19A1* (rs10046, rs700519 and
12 rs727479), *HSD3B2* (rs4659175), *HSD17B1* (rs2676531), and *HSD17B3* (rs4743709) in 261
13 participants and those of *HSD3B1* (rs6203), *HSD3B2* (rs1819698 and rs2854964), and *HSD17B1*
14 (rs605059 and rs676387) in 297 participants. The remaining 217 (= 514 – 297) participants were
15 excluded because they either had a cesarean birth, or their cord blood could not be collected
16 because they were registered in the cord blood bank. Cord blood in the blood bank was not
17 available for chemical analysis because the donors signed an agreement to allow its use for
18 patients who need a transplant. Of the 297 participants, 36 were not available or lacked sufficient
19 blood volume for the genetic analyses because of their use in previous studies. Cord blood
20 samples were collected at birth, and 400 μ L of each sample was used for genomic DNA extraction,
21 isolation, and purification using a QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden,
22 Germany) and a Maxwell 16 DNA purification kit (Promega, Madison, WI, USA) according to
23 the manufacturer's instructions [40]. Seven genotypes were evaluated, i.e., *CYP17A1* (rs743572),
24 *CYP19A1* (rs10046, rs700519, and rs727479), *HSD3B2* (rs4659175), *HSD17B1* (rs2676531), and
25 *HSD17B3* (rs4743709), using high-throughput pre-amplification gene expression
26 (Supplementary Method 1) and real-time PCR on dynamic chips (Supplementary Method 2),

1 whereas these five genotypes, i.e., *HSD3B1* (rs6203), *HSD3B2* (rs1819698 and rs2854964), and
2 *HSD17B1* (rs605059 and rs676387) were assessed using TaqMan gene expression measurements
3 (Supplementary Method 3).

4 5 **2.6. Measurement of cord serum sex hormone level**

6 The sex hormone levels in the cord blood samples were measured in 294 participants. Other
7 participants were excluded for the reasons stated in Section 2.5. The concentrations of P₄, DHEA,
8 A-dione, T, and E₂ were determined using LC/MS/MS according to the methods described
9 previously [1,2,41,42]. All measurements were performed by ASKA Pharma Medical Co. Ltd.
10 (Kanagawa, Japan). Samples below the limits of quantification (LOQ) were assigned values that
11 were 50% of their respective LOQs.

12 13 **2.7. Statistical analyses**

14 Of the 224 participants, two (0.9 %) had missing data on annual household income. Using
15 simple imputation, the participants were assigned to the annual household income group of < 5
16 million Japanese yen (the most frequent group). First, the associations between the variables in
17 males and females were analyzed using the independent *t*-test, Mann-Whitney *U*-test, and chi-
18 squared test. The association between maternal gestational weeks at blood sample collection and
19 PFOS, PFOA, and sex hormone levels were analyzed using Spearman's rank correlation
20 coefficients. Second, a chi-squared test was employed to test whether the frequency of genotype
21 distribution conformed to the Hardy-Weinberg equilibrium (HWE). Third, a case-control study
22 was set up with a lower than median A-dione level ($n_{case} = 109$), and the linkage disequilibrium
23 (LD) was evaluated using linkage analyses. Fourth, PFOS, PFOA, and sex hormone levels were
24 log₁₀-transformed before the following analyses because of their non-normal distribution.
25 Multiple linear regression analyses were used to evaluate the association between PFOS or
26 PFOA levels and sex hormone levels in both the crude and adjusted models. Maternal age,

1 maternal smoking during the third trimester, maternal alcohol consumption during pregnancy,
2 infant sex (only total infant), maternal blood sampling periods, and infant birth weight were
3 adjusted using the multiple linear regression analyses, except for in the crude models. Analyses
4 stratified by infant sex were also conducted. Fifth, multiple linear regression analyses were used
5 to evaluate the interaction between PFOS or PFOA levels and infant sex on sex hormone levels
6 in both the crude and adjusted models. The covariates were the same as those used in the fourth
7 analysis. Sixth, multiple linear regression analyses were used to evaluate the association
8 between the infant genotypes and PFOS, between them and PFOA, or between them and sex
9 hormone levels in both the crude and adjusted models. The covariates were the same as those
10 used in the fourth analysis. Analyses stratified by infant sex were also conducted. Maternal
11 sampling periods were excluded from the covariates only when the outcomes were PFOS or
12 PFOA levels. Seventh, multiple linear regression analyses were used to evaluate the interaction
13 between PFOS or PFOA levels and infant genotypes on sex hormone levels in both the crude
14 and adjusted models. The covariates were the same as those used in the fourth analysis.
15 Analyses stratified by infant sex were also conducted. In addition, multiple linear regression
16 analyses were used to evaluate the association between PFOS levels and sex hormone levels in
17 both the crude and adjusted models after stratification based on the infant genotype *CYP17A1*
18 (rs743572) because only the effect of the interactions between PFOS levels and infant genotype
19 *CYP17A1* (rs743572) on A-dione and T levels were statistically significant. The covariates were
20 the same as those used in the fourth analysis. Analyses stratified by infant sex were also
21 conducted.

22 The PFAS-sex interaction term was defined as “log₁₀-transformed PFOS or PFOA levels
23 (continuous) * sex (0 = males and 1 = females)” and PFAS-gene interaction term was defined as
24 “log₁₀-transformed PFOS or PFOA levels (continuous) * genotype (0 = referent genotype and 1
25 = genotype to be compared)”. The interaction term was included in the multiple linear
26 regression models except for the stratified analysis.

1 Furthermore, we refuted or confirmed the validity of the results in all participants, using
2 the sensitivity analyses by restricting participants to those that maternal blood samples were
3 collected during pregnancy (before delivery). Multiple linear regression analyses in the
4 sensitivity analyses were set up using the same covariates in the multiple linear regression
5 models in all participants.

6 Data were considered statistically significant at $p < 0.05$. The p -value for interaction was
7 also considered significant if $p < 0.05$. All statistical analyses were performed using SPSS
8 software version 26 (IBM Corp., Armonk, NY, USA), except for the linkage analyses. Linkage
9 analyses were performed using Haploview 4.2 software (Broad Institute of Massachusetts
10 Institute of Technology and Harvard, USA) [40].

12 **3. Results**

13 Characteristics of the study participants are shown in Table 1. Mean maternal age
14 (standard deviation; SD) was 30.0 (4.8) years of age. Median PFOS and PFOA levels (inter-
15 quartile range; IQR) in the maternal sera were 5.0 (3.3, 6.9) ng/mL and 1.4 (0.9, 2.0) ng/mL,
16 respectively. Median (IQR) PFOS levels did not differ between the 224 participants (5.0 [3.3,
17 6.9] ng/mL) included in the study and the 223 participants (5.5 [3.6, 7.2] ng/mL; $p = 0.174$)
18 excluded from the study. However, median (IQR) PFOA levels differed between the included
19 participants (1.4 [0.9, 2.0] ng/mL) and the excluded participants (1.2 [0.8, 1.6] ng/mL; $p =$
20 0.003; Supplementary Table 1). The median P₄, DHEA, A-dione, T, and E₂ (IQR) in the cord
21 sera were 217.8 (173.9, 282.4) ng/mL, 2.3 (1.8, 3.0) ng/mL, 0.45 (0.36, 0.57) ng/mL, 84.4 (59.5,
22 111.2) pg/mL, and 4.8 (3.3, 7.1) ng/mL, respectively. The male and female groups differed in
23 terms of median DHEA (2.1 ng/mL vs. 2.4 ng/mL; $p = 0.002$) and T (92.9 pg/mL vs. 73.1
24 pg/mL; $p < 0.001$) levels in the cord sera. Correlations between PFOS levels and gestational
25 age, between PFOA levels and gestational weeks at blood sample collection, and between sex

1 hormone levels and gestational weeks at blood sample collection were not statistically
2 significant (Supplementary Table 2).

3 Infant genotype frequencies are summarized in Table 2. The distribution of all 12 SNPs in
4 the 224 infants satisfied HWE (χ^2 -test: all $p > 0.05$).

5 The LD plot for the 12 SNPs is shown in Fig. 3. The LD parameter (D') for *CYP19A1*
6 (rs10046, rs700519, and rs727479) was 0.90-0.91. The D' values for *HSD3B2* (rs1819698,
7 rs2854964, and rs4659175) and *HSD17B1* (rs605059, rs676387, and rs2676531) were 0.97, and
8 0.99, respectively. Except for these values, D' was < 0.90 .

9 The effects of maternal PFOS and PFOA levels on infant sex hormone levels, stratified
10 by infant sex, are summarized in Table 3. Multiple linear regression analysis showed that the
11 PFOS levels were associated with lower P_4 (mean reduction = 0.400 [95% confidence interval
12 (CI): 0.201, 0.598]) and T/E₂ (mean reduction = 0.159 [95% CI: 0.005, 0.313]) levels, and
13 higher DHEA (mean increase = 0.359 [95% CI: 0.167, 0.552]), DHEA/A-dione (mean increase
14 = 0.338 [95% CI: 0.110, 0.565]), and E₂ (mean increase = 0.166 [95% CI: 0.005, 0.326]) after
15 adjustment for the covariates in all infants. This implies that the PFOS levels were associated
16 with lower P_4 (mean reduction = 0.270 [95% CI: 0.029, 0.512]) and T/E₂ (mean reduction =
17 0.305 [95% CI: 0.112, 0.497]) levels, and higher DHEA (mean increase = 0.249 [95% CI:
18 0.015, 0.483]) levels after adjusting for covariates in male infants. This also implies that the
19 PFOS levels were associated with lower P_4 (mean reduction = 0.517 [95% CI: 0.205, 0.829])
20 and higher DHEA (mean increase = 0.448 [95% CI: 0.146, 0.751]) levels after adjusting for the
21 covariates in female infants. We further performed a sensitivity analysis, the results of which
22 showed that the 95% confidence interval tended to be wider but did not change the original
23 results (Supplementary Table 3). Interestingly, for the T/E₂ levels, we observed a statistically
24 significant interaction between PFOS levels and infant sex only after adjusting for the covariates
25 (p for interaction [p_{int}] = 0.045; Supplementary Table 4). In addition, there was no association

1 between PFOA levels and sex hormone levels after adjustment for covariates. The results were
2 confirmed using sensitivity analysis (Supplementary Table 5).

3 The combined associations of PFOS levels and infant genotype *CYP17A1* (rs743572) on
4 sex hormone levels in female infants are presented in Table 4 (see also Fig. 4A and 4B).
5 Multiple linear regression analysis showed a significant association between the interaction
6 between PFOS levels and infant genotype *CYP17A1* (rs743572) on the A-dione and T levels
7 after adjustment for the covariates in female infants. When the interaction between PFOS levels
8 and infant genotype *CYP17A1* (rs743572) on the A-dione levels was considered after
9 adjustment for the covariates, the estimated changes (95% CI) in the A-dione levels per one unit
10 increase in PFOS levels had a mean increase of 0.445 (0.102, 0.787), those in the A-dione levels
11 of infant genotype *CYP17A1* (rs743572)-AG/GG compared to AA had a mean increase of 0.396
12 (0.084, 0.707), and those in the A-dione levels of the interaction term between PFOS and
13 *CYP17A1* (rs743572)-AG/GG had a mean reduction of 0.579 (0.161, 0.997) ($p_{int} = 0.007$).
14 When the interaction between PFOS levels and infant genotype *CYP17A1* (rs743572) on the T
15 levels was considered after adjustment for the covariates, the estimated changes (95% CI) in the
16 T levels per one unit increase in PFOS levels had a mean increase of 0.641 (0.191, 1.091), those
17 in the T levels of infant genotype *CYP17A1* (rs743572)-AG/GG compared to AA had a mean
18 increase of 0.595 (0.186, 1.003), and those in the A-dione levels of the interaction term between
19 PFOS and *CYP17A1* (rs743572)-AG/GG had a mean reduction of 0.856 (0.307, 1.404) ($p_{int} =$
20 0.003). The results were confirmed using sensitivity analysis (Supplementary Table 6). There
21 was no statistically significant interaction between PFOS levels and 11 SNPs of *CYP19A1*,
22 *HSD3B1*, *HSD3B2*, *HSD17B1*, and *HSD17B3* on sex hormone levels (data not shown). In
23 addition, there was no statistically significant interaction between PFOA levels and any of the
24 12 SNPs on sex hormone levels (data not shown).

25 The effects of maternal PFOS levels on infant sex hormone levels stratified by the female
26 infant genotype *CYP17A1* (rs743572) are shown in Table 5. The estimated changes in A-dione

1 levels per one-unit increase of PFOS levels (95% CI) were a mean increase of 0.494 (0.059,
2 0.930) in female infants with the AA genotype. The estimated changes in T levels per one-unit
3 increase of PFOS levels (95% CI) were a mean increase of 0.679 (0.176, 1.187) in female
4 infants with the AA genotype. However, there were not significant change in A-dione and T
5 levels in female infants with the AG/GG genotype. The results were confirmed using sensitivity
6 analysis (Supplementary Table 7).

7

8 **4. Discussion**

9 In this study, we observed that the interaction between the prenatal PFOS levels and the infant
10 genotype *CYP17A1* (rs743572) influenced the A-dione and T levels in all participants and
11 female infants. Therefore, these gene-environment interactions exhibit sex differences.

12 To the best of our knowledge, only five studies have explored the association between
13 prenatal exposure to PFASs and sex hormone levels [1-5]. In our previous studies, we have
14 revealed that an increase in prenatal PFOS exposure (median: 5.2 ng/mL) was associated with
15 increased cord DHEA levels in all participants and cord E₂ levels in male infants and decreased
16 cord P₄ levels in all participants. An increase in prenatal PFOA exposure (median: 1.4 ng/mL)
17 was associated with decreased cord DHEA levels [1,2]. Contrary to our results and previous
18 reports, Kristensen et al. [4] observed that increased DHEA levels were not associated with
19 higher PFOS (median: 21.1 ng/mL) and PFOA (median: 3.6 ng/mL) exposure. This is the first
20 study to investigate sex differences in the association between prenatal PFAS levels and fetal
21 sex hormone levels.

22 Two studies have evaluated the influence of prenatal exposure to PFOS and PFOA on
23 hormone levels among 15-year-old girls (median: 19.2 ng/mL for PFOS; 3.6 ng/mL for PFOA)
24 [3] and adult men (median: 21.2 ng/mL for PFOS; 3.8 ng/mL for PFOA) [5]. They found that
25 increased prenatal PFOS and PFOA exposures were associated with increased T levels in 15-
26 year-old girls, but no change in T and E₂ levels was found in adult men [3,5]. In this study,

1 increased PFOS levels (median: 5.4 ng/mL), but not PFOA levels (median:1.4 ng/mL), were
2 associated with P₄, DHEA, DHEA/A-dione, E₂, and T/E₂ levels. Therefore, these results are in
3 partial accordance with those of the present study. Differences in the PFOA exposure IQR range
4 (0.9-2.1 ng/mL in this study vs. 2.7-4.7 ng/mL reported by Maisonet et al. [3] and Vested et al.
5 [5]) could contribute to the discrepancies in the findings of the different studies.

6 The effects of the infant genotype *CYP17A1* (rs743572) on maternal PFOS and PFOA
7 levels were not observed (Supplementary Table 8). The *CYP17A1* mRNA or protein expression
8 levels of CYP17A1 were reduced in rodents administered with more than 5 or 10 mg/kg PFOS
9 daily [44,45]. CYP17 catalyzes the conversion of P₄ to A-dione via an intermediate product [7].
10 Increased PFOS levels may decrease *CYP17A1* mRNA, CYP17A1 protein levels, the enzymatic
11 activation of CYP17A1, and the production of A-dione and T, which are located downstream of
12 A-dione.

13 The 5'-untranslated region of the *CYP17* gene contains *CYP17A1* (A>G, rs743572) [46].
14 It locates an Sp1-type (CCACC box) promoter site 34-base pair upstream of the initiation site of
15 translation [46]. This base pair change creates a CCACC box. It is supposed that the number of
16 5' promoter elements correlates with the promoter activity [47]. Increased PFOS levels may
17 affect the 5'-untranslated regions of *CYP17*, cause a decrease in the promoter activity of its
18 gene, and then decrease the enzymatic CYP17A1 activation.

19 To date, there are no reports on the association between *CYP17A1* (rs743572) and
20 promoter activity. In previous epidemiological studies, postmenopausal women with the
21 *CYP17A1* GG genotype had higher levels of estrone compared to those with the *CYP17A1* AA
22 genotype [48] and postmenopausal women with the *CYP17A1* AG or GG genotype had higher
23 levels of E₂ [49,50]. E₂ is located downstream of A-dione and T [7]. Previous studies have
24 shown that enzymatic CYP17A1 activation may be higher in the infant genotype *CYP17A1*
25 (rs743572) AG/GG than in AA.

1 A-dione and T levels in the cord sera were not influenced by the infant genotype
2 *CYP17A1* (rs743572) and PFOS levels in maternal blood (Supplementary Table 8). The
3 *CYP17A1* (rs743572) genotype was not associated with DHEA or A-dione levels in four
4 previous studies [8,48,51,52]. The results of these previous studies are similar to those of the
5 present study.

6 Cord sera T levels, but not cord sera A-dione levels, were influenced by infant sex.
7 Interaction analysis did not reveal any interaction between maternal PFOS levels and infant sex
8 on infant A-dione and T levels. This result suggests that no interaction exist between infant sex
9 and maternal sera PFOS levels during pregnancy in A-dione and T levels in the cord sera.

10 We found an interaction between maternal sera PFOS levels and the infant genotype
11 *CYP17A1* (rs743572) on infant A-dione and T levels. For this genotype, there was an obvious
12 positive correlation with A-dione and T levels in the AA genotype, but no obvious negative
13 correlation with A-dione and T levels in the AG/GG genotype. This result implies that
14 interactions might exist between the infant genotype *CYP17A1* (rs743572) and maternal sera
15 PFOS levels during pregnancy in A-dione and T levels in the cord sera.

16 In female infants, the regression coefficient of PFOS and the *CYP17A1* genotype on A-
17 dione or T levels showed a positive main effect but showed a negative interaction term (Table
18 4). This indicates that the effect of PFOS on A-dione or T becomes positive or negative
19 depending on the *CYP17A1* genotype. In the AA genotype, there was a significant association
20 between PFOS and A-dione or T, and the positive change in A-dione or T levels by PFOS was
21 small (Table 5). In the AG/GG genotype, the negative change in A-dione or T levels by PFOS
22 was not significant (Table 5). It can be interpreted that the relationship between PFOS and A-
23 dione or T levels changes significantly in the negative direction when changing from AA to
24 AG/GG genotype (Table 5 and Fig. 4A and 4B). We speculated that the *CYP17A1* genotype
25 canceled the negative interaction term shown in the effects. Therefore, it was considered that
26 AA genotype might be a genetically susceptible population that is easily affected by A-dione or

1 T levels by the increase in PFOS levels, suggesting a possible biological mechanism underlying
2 this finding.

3 Many studies have determined the genetic susceptibility of genotypes *CYP19A1* (rs10046,
4 rs700519, and rs727479), *HSD3B1* (rs6203), *HSD3B2* (rs1819698 and rs2854964), *HSD17B1*
5 (rs605059, rs676387, and rs2676531), and *HSD17B3* (rs4743709) [18,19,21-25,27]. However,
6 these genotypes did not modify the association between PFOS and sex hormone levels in our
7 study. In this study, the maternal PFOS levels in the blood sera were low, and approximately
8 30% of PFOS was transferred to the fetus from the mother through the placenta [39]; therefore,
9 their genotypes and low PFOS levels in the fetuses might not be influenced by sex hormone
10 levels.

11 One of the main strengths of this study is the accurate measurement of blood PFOS and
12 PFOA levels using LC/MS/MS. Furthermore, we minimized bias using a prospective birth
13 cohort study design. However, this study has several limitations. First, we measured cord sex
14 hormone levels. Hormone levels changed from the end of gestation to after birth [53]. The
15 association between sex hormone levels and gestational age is not significant in this study, and
16 hence, the effects of individual hormonal variations (inter-individual variations) among the
17 participants depending on the gestational age are limited. However, when interpreting our
18 results, it should be noted that hormonal variations within an individual (intra-individual
19 variations) change within short periods, and thus, hormonal variation might not be accurately
20 reflected by a single measurement. Second, although the percentage of smokers and alcohol
21 consumers in our cohort, that is the Hokkaido region, tended to be the highest among all the
22 other regions in Japan [54], neither smoking nor alcohol consumption status affected our results
23 (data not shown). Third, there are problems with multiple comparisons. Since it is a multiple
24 comparison, the *p*-values of PFAS levels, genotype, and sex hormone levels must be corrected.
25 When two or more SNPs are in strong LD, if one SNP can be known, information on the other
26 SNPs can be determined (tagSNP). Even if tagSNP is used, the number of SNPs remains nine.

1 Thus, the number of patterns for the combinations of exposure, tagSNPs, and sex hormones was
2 90. For the Bonferroni correction, $p \leq 0.0005$ ($= 0.05/90$) was significant. When these
3 corrections were applied, the results of this study were not significant. Finally, since the results
4 have not been replicated in any external cohort thus far, the generalizability of the results is
5 limited. We consider that the results of this study can be adapted for a similar population with
6 comparable exposure, outcome, and genetic distribution.

7 8 **5. Conclusion**

9 For the first time, we showed that the infant genotype *CYP17A1* (rs743572) and sex
10 differences play an important role in determining how maternal PFOS exposure during
11 pregnancy influences fetal sex hormone levels.

12 13 **Authors' contributions**

14 S.K. contributed to the study design, data acquisition, analysis, interpretation, and manuscript
15 drafting. F.S., A.A., C.M., S.I., and H.G. contributed substantially to data acquisition, analysis,
16 and interpretation. Y.I. contributed to data analysis. T.M., K.M., N.S., and K.C. contributed to data
17 acquisition. R.K. made substantial contributions to the conception of the study design, data
18 acquisition, analysis, interpretation, and supervision. All authors critically revised the manuscript
19 and approved the final version for publication.

20 21 **Acknowledgements**

22 The authors thank the mothers and the infants who participated in the Hokkaido Study on
23 Environment and Children's Health, and the staff of Sapporo Toho Hospital.

24 25 **Funding**

26 This work was supported by the Japanese Ministry of Health, Labour, and Welfare, Health and

1 Labour Sciences Research Grants (No. H29 Kagaku-Ippan-002), Scientific Research from the
2 Japan Society for the Promotion of Sciences, the Ministry of Education, Culture, Sports, Science
3 and Technology (Nos. 15K15220, 18H03035, 18K17348, 19H01071, 19K22730, 20K10445,
4 2589300403, and 26740028); and the Environment Research and Technology Development Fund
5 of the Ministry of the Environment, Government of Japan (Nos. 5C-1252 and 5-1554). The
6 funders had no role in the study design, data collection, data analysis, decision to publish, or
7 manuscript preparation.

8

9 **Conflicts of interest**

10 The authors declare no conflicts of interest.

11

12 **Data statement**

13 The data and materials used to derive our conclusions are unsuitable for public deposition due to
14 ethical restrictions and specific legal framework in Japan. It is prohibited by the Act on the
15 Protection of Personal Information (Act No. 57 of May 30, 2003, amended on September 9, 2015)
16 to publicly deposit data containing personal information. The Ethical Guidelines for
17 Epidemiological Research enforced by the Japan Ministry of Education, Culture, Sports, Science
18 and Technology and the Ministry of Health, Labour and Welfare also restrict the open sharing of
19 the epidemiologic data. All inquiries about access to data should be sent to
20 rkishi@med.hokudai.ac.jp. The person responsible for handling inquiries sent to this e-mail
21 address is Professor Reiko Kishi, Principal Investigator of the Hokkaido Study on Environment
22 and Children's Health, Center for Environmental and Health Sciences, Hokkaido University.

23

24

25 **References**

- 1 [1] H. Goudarzi, A. Araki, S. Itoh, S. Sasaki, C. Miyashita, T. Mitsui, H. Nakazawa, K.
2 Nonomura, R. Kishi, The association of prenatal exposure to perfluorinated chemicals with
3 glucocorticoid and androgenic hormones in cord blood samples: the Hokkaido study. *Environ.*
4 *Health Perspect.* 125 (1) (2017) 111-118.
5
- 6 [2] S. Itoh, A. Araki, T. Mitsui, C. Miyashita, H. Goudarzi, S. Sasaki, K. Cho, H. Nakazawa, Y.
7 Iwasaki, N. Shinohara, K. Nonomura, R. Kishi, Association of perfluoroalkyl substances exposure
8 in utero with reproductive hormone levels in cord blood in the Hokkaido study on environment
9 and children's health. *Environ. Int.* 94 (2016) 51-59.
10
- 11 [3] M. Maisonet, A.M. Calafat, M. Marcus, J.J.K. Jaakkola, H. Lashen, Prenatal exposure to
12 perfluoroalkyl acids and serum testosterone concentrations at 15 years of age in female ALSPAC
13 study participants. *Environ. Health Perspect.* 123 (12) (2015) 1325-1330.
14
- 15 [4] S.L. Kristensen, C.H. Ramlau-Hansen, E. Ernst, S.F. Olsen, J.P. Bonde, A. Vested, T.I.
16 Halldorsson, G. Becher, L.S. Haug, G. Toft, Long-term effects of prenatal exposure to
17 perfluoroalkyl substances on female reproduction. *Hum. Reprod.* 28 (12) (2013) 3337-3348.
18
- 19 [5] A. Vested, C.H. Ramlau-Hansen, S.F. Olsen, J.P. Bonde, S.L. Kristensen, T.I. Halldorsson, G.
20 Becher, L.S. Haug, E.H. Ernst, G. Toft, Associations of in utero exposure to perfluorinated alkyl
21 acids with human semen quality and reproductive hormones in adult men. *Environ. Health*
22 *Perspect.* 121 (4) (2013) 453-458.
23
- 24 [6] N. Washino, Y. Saijo, S. Sasaki, S. Kato, S. Ban, K. Konishi, R. Ito, A. Nakata, Y. Iwasaki, K.
25 Saito, H. Nakazawa, R. Kishi, Correlations between prenatal exposure to perfluorinated chemicals
26 and reduced fetal growth. *Environ. Health Perspect.* 117 (4) (2009) 660-667.

1

2 [7] S.H. Olson, E.V. Bandera, I. Orlow, Variants in estrogen biosynthesis genes, sex steroid
3 hormone levels, and endometrial cancer: a HuGE review. *Am. J. Epidemiol.* 165 (3) (2007) 235-
4 245.

5

6 [8] A.M. Dunning, M. Dowsett, C.S. Healey, L. Tee, R.N. Luben, E. Folkerd, K.L. Novik, L.
7 Kelemen, S. Ogata, P.D.P. Pharoah, D.F. Easton, N.E. Day, B.A.J. Ponder, Polymorphisms
8 associated with circulating sex hormone levels in postmenopausal women. *J. Natl. Cancer Inst.*
9 96 (12) (2004) 936-945.

10

11 [9] C.A. Haiman, S.E. Hankinson, D. Spiegelman, G.A. Colditz, W.C. Willett, F.E. Speizer, K.T.
12 Kelsey, D.J. Hunter, The relationship between a polymorphism in CYP17 with plasma hormone
13 levels and breast cancer. *Cancer Res.* 59 (5) (1999) 1015-1020.

14

15 [10] L. Xu, D.M. Krenitsky, A.M. Seacat, J.L. Butenhoff, M.W. Anders, Biotransformation of
16 N-ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol, and
17 slices and by expressed rat and human cytochromes P450. *Chem. Res. Toxicol.* 17 (6) (2004)
18 767-775.

19

20 [11] J.P. Benskin, A. Holt, J.W. Martin, Isomer-specific biotransformation rates of a
21 perfluorooctane sulfonate (PFOS)-precursor by cytochrome P450 isozymes and human liver
22 microsomes. *Environ. Sci. Technol.* 43 (22) (2009) 8566-8572.

23

24 [12] Z. Fu, Y. Wang, Z. Wang, H. Xie, J. Chen, Transformation pathways of isomeric
25 perfluorooctanesulfonate precursors catalyzed by the active species of P450 enzymes: in silico
26 investigation. *Chem. Res. Toxicol.* 28 (3) (2015) 482-489.

- 1
- 2 [13] J.S. Kang, J.S. Choi, J.W. Park, Transcriptional changes in steroidogenesis by
3 perfluoroalkyl acids (PFOA and PFOS) regulate the synthesis of sex hormones in H295R cells.
4 *Chemosphere*. 155 (2016) 436-443.
- 5
- 6 [14] H. Zhang, H. Lu, P. Chen, X. Chen, C. Sun, R.S. Ge, Z. Su, L. Ye, Effects of gestational
7 perfluorooctane sulfonate exposure on the developments of fetal and adult Leydig cells in F1
8 males. *Environ. Pollut.* 262 (2020) 114241.
- 9
- 10 [15] H.T. Wan, Y.G. Zhao, M.H. Wong, K.F. Lee, W.S. Yeung, J.P. Giesy, C.K. Wong, Testicular
11 signaling is the potential target of perfluorooctanesulfonate-mediated subfertility in male mice.
12 *Biol. Reprod.* 84 (5) (2011)1016-1023.
- 13
- 14 [16] R. Loja-Chango, F.R. Pérez-López, T. Simoncini, G.S. Escobar, P. Chedraui, Increased
15 mood symptoms in postmenopausal women related to the polymorphism rs743572 of the
16 CYP17 A1 gene. *Gynecol. Endocrinol.* 32 (10) (2016) 827-830.
- 17
- 18 [17] R. Rai, K.L. Sharma, S. Misra, A. Kumar, B. Mittal, CYP17 polymorphism (rs743572) is
19 associated with increased risk of gallbladder cancer in tobacco users. *Tumour. Biol.* 35 (7) (2014)
20 6531-6537.
- 21
- 22 [18] Z. Pan, Z. Fu, Q. Song, W. Cao, W. Cheng, X. Xu, Genetic polymorphisms and haplotype of
23 hormone-related genes are associated with the risk of breast cancer in Chinese women. *Genet.*
24 *Mol. Res.* 15 (2) (2016) gmr8640.
- 25
- 26 [19] S. Chattopadhyay, S. Siddiqui, M.S. Akhtar, M Z. Najm, S.V.S. Deo, N.K. Shukla, S.A.

1 Husain, Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast
2 cancer: a case control study from North India. *Tumour Biol.* 35 (5) (2014) 4517-4527.
3
4 [20] H.S. Wang, H.M. Wu, B.H. Cheng, C.F. Yen, P.Y. Chang, A. Chao, Y.S. Lee, H.D. Huang,
5 T.H. Wang, Functional analyses of endometriosis-related polymorphisms in the estrogen synthesis
6 and metabolism-related genes. *PLoS One.* 7 (11) (2012) e47374.
7
8 [21] V.W. Setiawan, J.A. Doherty, X.O. Shu, M.R. Akbari, C. Chen, I. De Vivo, A. Demichele, M.
9 Garcia-Closas, M.T. Goodman, C.A. Haiman, S.E. Hankinson, B.E. Henderson, P.L. Horn-Ross,
10 J.V. Lacey Jr, L. Le Marchand, D.A. Levine, X. Liang, J. Lissowska, G. Lurie, M. McGrath, S.A.
11 Narod, T.R. Rebbeck, G. Ursin, N.S. Weiss, Y.B. Xiang, H.P. Yang, W. Zheng, S.H. Olson, Two
12 estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the
13 epidemiology of endometrial cancer consortium. *Cancer Epidemiol. Biomarkers Prev.* 18 (1)
14 (2009) 242-247.
15
16 [22] M. Shimodaira, T. Nakayama, N. Sato, N. Aoi, M. Sato, Y. Izumi, M. Soma, K. Matsumoto,
17 Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension,
18 aldosterone level, and left ventricular structure. *Eur. J. Endocrinol.* 163 (4) (2010) 671-680.
19
20 [23] M. Osiński, A. Mostowska, P. Wirstlein, J. Skrzypczak, P.P. Jagodziński, M. Szczepańska,
21 Involvement of 17 β -hydroxysteroid dehydrogenase type gene 1 937 A>G polymorphism in
22 infertility in Polish caucasian women with endometriosis. *J. Assist. Reprod. Genet.* 34 (6)
23 (2017) 789-794.
24

- 1 [24] L.S. Zhang, F. Yuan, X. Guan, J. Li, X.L. Liu, J. Sun, B. Liu, W. Ma, F.M. Deng,
2 Association of genetic polymorphisms in HSD17B1, HSD17B2 and SHBG genes with
3 hepatocellular carcinoma risk. *Pathol. Oncol. Res.* 20 (3) (2014) 661-666.
4
- 5 [25] F. Sata, N. Kurahashi, S. Ban, K. Moriya, K.D. Tanaka, M. Ishizuka, H. Nakao, Y. Yahata,
6 H. Imai, H. Kakizaki, K. Nonomura, R. Kishi, Genetic polymorphisms of 17 β -hydroxysteroid
7 dehydrogenase 3 and the risk of hypospadias. *J. Sex. Med.* 7 (8) (2010) 2729-2738.
8
- 9 [26] M. Shimodaira, T. Nakayama, I. Sato, N. Sato, N. Izawa, Y. Mizutani, K. Furuya, T.
10 Yamamoto, Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive
11 disorders of pregnancy. *Endocrine.* 42 (3) (2012) 700-707.
12
- 13 [27] T. Heinosalo, N. Saarinen, M. Poutanen, Role of hydroxysteroid (17 β) dehydrogenase
14 type 1 in reproductive tissues and hormone-dependent diseases. *Mol. Cell Endocrinol.* 489 (2019)
15 9-31.
16
- 17 [28] K. Xia, Y. Yu, M. Ahn, H. Zhu, F. Zou, J.H. Gilmore, R.C. Knickmeyer, Environmental and
18 genetic contributors to salivary testosterone levels in infants. *Front. Endocrinol. (Lausanne)* 5
19 (2014) 187.
20
- 21 [29] H.G. Hilton, L.A. Guethlein, A. Goyos, N. Nemat-Gorgani, D.A. Bushnell, P.J. Norman, P.
22 Parham, Polymorphic HLA-C receptors balance the functional characteristics of KIR
23 haplotypes. *J. Immunol.* 195 (7) (2015) 3160–3170.
24
- 25 [30] S. Cooley, D.J. Weisdorf, L.A. Guethlein, J.P. Klein, T. Wang, S.G.E. Marsh, S. Spellman,
26 M.D. Haagenson, K. Saetern, M. Ladner, E. Trachtenberg, P. Parham, J.S. Miller, Donor killer

1 cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the
2 clinical benefit of unrelated transplantation for acute myelogenous leukemia. *J. Immunol.* 192
3 (10) (2014) 4592-4600.

4

5 [31] S. Kobayashi, F. Sata, S. Sasaki, T.S. Braimoh, A. Araki, C. Miyashita, H. Goudarzi, S.
6 Kobayashi, R. Kishi, Combined effects of AHR, CYP1A1, and XRCC1 genotypes and prenatal
7 maternal smoking on infant birth size: Biomarker assessment in the Hokkaido study. *Reprod.*
8 *Toxicol.* 65 (2016) 295-306.

9

10 [32] S. Kobayashi, F. Sata, C. Miyashita, S. Sasaki, S. Ban, A. Araki, H. Goudarzi, J. Kajiwara,
11 T. Todaka, R. Kishi, Dioxin-metabolizing genes in relation to effects of prenatal dioxin levels
12 and reduced birth size: the Hokkaido study. *Reprod. Toxicol.* 67 (2017) 111-116.

13

14 [33] S. Kobayashi, F. Sata, S. Sasaki, T.S. Braimoh, A. Araki, C. Miyashita, H. Goudarzi, S.
15 Kobayashi, R. Kishi, Modification of adverse health effects of maternal active and passive
16 smoking by genetic susceptibility: dose-dependent association of plasma cotinine with infant
17 birth size among Japanese women-the Hokkaido study. *Reprod. Toxicol.* 74 (2017) 94-103.

18

19 [34] S. Kobayashi, F. Sata, H. Goudarzi, A. Araki, C. Miyashita, S. Sasaki, E. Okada, Y. Iwasaki,
20 T. Nakajima, R. Kishi, Associations among perfluorooctanesulfonic/perfluorooctanoic acid levels,
21 nuclear receptor gene polymorphisms, and lipid levels in pregnant women in the Hokkaido study.
22 *Sci. Rep.* 11 (1) (2021) 9994.

23

24 [35] S. Sasaki, M. Limpar, F. Sata, S. Kobayashi, R. Kishi, Interaction between maternal caffeine
25 intake during pregnancy and CYP1A2 C164A polymorphism affects infant birth size in the
26 Hokkaido study. *Pediatr. Res.* 82 (1) (2017) 19-28.

- 1
- 2 [36] R. Kishi, S. Sasaki, E. Yoshioka, M. Yuasa, F. Sata, Y. Saijo, N. Kurahashi, J. Tamaki, T.
3 Endo, K. Sengoku, K. Nonomura, H. Minakami, for the Hokkaido study on environment and
4 children's health, Cohort profile: the Hokkaido study on environment and children's health in
5 Japan. *Int. J. Epidemiol.* 40 (3) (2011) 611-618.
- 6
- 7 [37] R. Kishi, S. Kobayashi, T. Ikeno, A. Araki, C. Miyashita, S. Itoh, S. Sasaki, E. Okada, S.
8 Kobayashi, I. Kashino, K. Itoh, S. Nakajima, members of the Hokkaido study on environment
9 and children's health, Ten years of progress in the Hokkaido birth cohort study on environment
10 and children's health: cohort profile--updated 2013. *Environ. Health Prev. Med.* 18 (6) (2013)
11 429-450.
- 12
- 13 [38] R. Kishi, A. Araki, M. Minatoya, T. Hanaoka, C. Miyashita, S. Itoh, S. Kobayashi, Y. Ait
14 Bamai, K. Yamazaki, R. Miura, N. Tamura, K. Ito, H. Goudarzi, members of the Hokkaido study
15 on environment and children's health, The Hokkaido birth cohort study on environment and
16 children's health: cohort profile--updated 2017. *Environ. Health Prev. Med.* 22 (1) (2017) 46.
- 17
- 18 [39] K. Inoue, F. Okada, R. Ito, S. Kato, S. Sasaki, S. Nakajima, A. Uno, Y. Saijo, F. Sata, Y.
19 Yoshimura, R. Kishi, H. Nakazawa, Perfluorooctane sulfonate (PFOS) and related
20 perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS
21 exposure in a susceptible population during pregnancy. *Environ. Health Perspect.* 112 (11)
22 (2004) 1204-1207.
- 23
- 24 [40] S. Kobayashi, F. Sata, S. Sasaki, S. Ban, C. Miyashita, E. Okada, M. Limpar, E. Yoshioka,
25 J. Kajiwara, T. Todaka, Y. Saijo, R. Kishi, Genetic association of aromatic hydrocarbon receptor
26 (AHR) and cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) polymorphisms

1 with dioxin blood concentrations among pregnant Japanese women. *Toxicol. Lett.* 219 (3)
2 (2013) 269-278.

3

4 [41] A. Araki, T. Mitsui, C. Miyashita, T. Nakajima, H. Naito, S. Ito, S. Sasaki, K. Cho, T.
5 Ikeno, K. Nonomura, R. Kishi, Association between maternal exposure to di(2-ethylhexyl)
6 phthalate and reproductive hormone levels in fetal blood: the Hokkaido study on environment
7 and children's health. *PLoS One.* 9 (10) (2014) e109039.

8

9 [42] C. Miyashita, A. Araki, T. Mitsui, S. Itoh, H. Goudarzi, S. Sasaki, J. Kajiwara, T. Hori, K.
10 Cho, K. Moriya, N. Shinohara, K. Nonomura, R. Kishi, Sex-related differences in the associations
11 between maternal dioxin-like compounds and reproductive and steroid hormones in cord blood:
12 the Hokkaido study. *Environ. Int.* 117 (2018) 175-185.

13

14 [43] Broad Institute of Massachusetts Institute of Technology and Harvard, US. Haploview 4.2.
15 software. <https://www.broadinstitute.org/haploview/haploview> (accessed 27 Apr 2021)

16

17 [44] H.T. Wan, Y.G. Zhao, M.H. Wong, K.F. Lee, W.S.B. Yeung, J.P. Giesy, C.K.C. Wong,
18 Testicular signaling is the potential target of perfluorooctanesulfonate-mediated subfertility in
19 male mice. *Biol. Reprod.* 84 (5) (2011) 1016-1023.

20

21 [45] L. Li, X. Li, X. Chen, Y. Chen, J. Liu, F. Chen, F. Ge, L. Ye, Q. Lian, R.S. Ge, Perfluorooctane
22 sulfonate impairs rat Leydig cell development during puberty. *Chemosphere* 190 (2018) 43-53.

23

24 [46] A.H. Carey, D. Waterworth, K. Patel, D. White, J. Little, P. Novelli, S. Franks, R. Williamson,
25 Polycystic ovaries and premature male pattern baldness are associated with one allele of the
26 steroid metabolism gene CYP17. *Hum. Mol. Genet.* 3 (10) (1994) 1873-1876.

- 1
- 2 [47] J.T. Kadonaga, K.A. Jones, R. Tjian, Promoter-specific activation of RNA polymerase II
3 transcription by Sp1. *Trends Biochem. Sci.* 11 (1) (1986) 20-23.
- 4
- 5 [48] C.A. Haiman, S.E. Hankinson, G.A. Colditz, D.J. Hunter, I. De Vivo, A polymorphism in
6 CYP17 and endometrial cancer risk. *Cancer Res.* 61 (10) (2001) 3955-3960.
- 7
- 8 [49] H.S. Feigelson, L.S. Shames, M.C. Pike, G.A. Coetzee, F.Z. Stanczyk, B.E. Henderson,
9 Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and
10 progesterone concentrations. *Cancer Res.* 58 (4) (1998) 585-587.
- 11
- 12 [50] C.C. Hong, H.J. Thompson, C. Jiang, G.L. Hammond, D. Tritchler, M. Yaffe, N.F. Boyd,
13 Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene
14 and risk factors for breast cancer. *Breast Cancer Res. Treat.* 88 (3) (2004) 217-230.
- 15
- 16 [51] M. García-Closas, J. Herbstman, M. Schiffman, A. Glass, J.F. Dorgan, Relationship
17 between serum hormone concentrations, reproductive history, alcohol consumption and genetic
18 polymorphisms in pre-menopausal women. *Int. J. Cancer.* 102 (2) (2002) 172-178.
- 19
- 20 [52] S.S. Tworoger, J. Chubak, E.J. Aiello, C.M. Ulrich, C. Atkinson, J.D. Potter, Y. Yasui, P.L.
21 Stapleton, J.W. Lampe, F.M. Farin, F.Z. Stanczyk, A. McTiernan, Association of CYP17, CYP19,
22 CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in
23 postmenopausal women. *Cancer Epidemiol. Biomarkers Prev.* 13 (1) (2004) 94-101.
- 24
- 25 [53] E.A.M. Kuijper, J.C.F. Ket, M.R. Caanen, C.B. Lambalk, Reproductive hormone
26 concentrations in pregnancy and neonates: a systematic review. *Reprod. Biomed. Online.* 27 (1)

1 (2013) 33-63.

2

3 [54] M. Matsuzaki, M. Haruna, E. Ota, R. Murayama, T. Yamaguchi, I. Shioji, S. Sasaki, T.

4 Yamaguchi, S. Murashima, Effects of lifestyle factors on urinary oxidative stress and serum

5 antioxidant markers in pregnant Japanese women: a cohort study. *Biosci. Trends.* 8 (3) (2014)

6 176-184.

7

8

1 **Figure Legends**

2 **Fig. 1. Simplified schematic pathway of sex steroid biosynthesis**

3

4 Abbreviations: CYP17A1, cytochrome P450 17A1; CYP19A1, cytochrome P450 19A1;
5 HSD3B1, 3 β -hydroxysteroid dehydrogenase type 1; HSD3B2, 3 β -hydroxysteroid dehydrogenase
6 type 2; HSD17B1, 17 β -hydroxysteroid dehydrogenase type 1, and HSD17B3, 17 β -
7 hydroxysteroid dehydrogenase type 3.

8

9 **Fig. 2. Participant selection flow diagram**

10

11 **Fig. 3. Linkage disequilibrium (LD) plot for the *CYP17A1* (dbSNP ID: rs743572), *CYP19A1*
12 (dbSNP ID: rs10046, rs700519, and rs727479), *HSD3B1* (dbSNP ID: rs6203), *HSD3B2*
13 (dbSNP ID: rs1819698, rs2854964, and rs4659175), *HSD17B1* (dbSNP ID: rs605059,
14 rs676387, and rs2676531), and *HSD17B3* (dbSNP ID: rs4743709) single nucleotide
15 polymorphisms (SNPs) in infants**

16

17 The LD parameter (D') value is provided within the boxes ($-1 \leq D' \leq 1$).

18 A D' of 1 represents perfect genetic linkage.

19 A D' of 0.90, 0.91, 0.97, and 0.99 (as indicated 90, 91, 97, and 99 in this figure) represents
20 approximately perfect genetic linkage.


21

22 **Fig. 4. Interaction plots of maternal PFOS levels during pregnancy and infant *CYP17A1*
23 (rs743572) genotype on (A) A-dione or (B) T levels in cord blood in female infants**

24


25

1 Fig. 1




2

1 Fig. 2




2

1 Fig. 3



2


1 Fig. 4 (A)



- (Solid line): AA genotype
Log₁₀-transformed A-dione levels (ng/mL)
 $= -0.598 + 0.402 \times \text{Log}_{10}\text{-transformed PFOS levels (ng/mL)}$
- ▲ (Dotted line): AG/GG genotype
Log₁₀-transformed A-dione levels (ng/mL)
 $= -0.209 - 0.177 \times \text{Log}_{10}\text{-transformed PFOS levels (ng/mL)}$

2

1 Fig. 4 (B)



- (Solid line): AA genotype
 Log_{10} -transformed T levels (pg/mL)
 $= 1.452 + 0.578 \times \text{Log}_{10}$ -transformed PFOS levels (ng/mL)
- ▲ (Dotted line): AG/GG genotype
 Log_{10} -transformed T levels (pg/mL)
 $= 2.053 - 0.290 \times \text{Log}_{10}$ -transformed PFOS levels (ng/mL)

2

1 Table 1. Characteristics of study participants

Characteristics	Total (<i>n</i> = 224)	Infants		<i>p</i> value ^a
		Males (<i>n</i> = 100)	Females (<i>n</i> = 124)	
Mothers				
Age (years) ^b	30.0 ± 4.8	30.5 ± 4.7	29.5 ± 4.7	0.103
Pre-pregnancy body mass index (BMI) (kg/m ²) ^b	20.4 ± 2.9	20.9 ± 2.6	21.0 ± 3.1	0.809
Smokers during the third trimester of pregnancy ^c				
No	186 (83.0)	87 (87.0)	99 (79.8)	0.156
Yes	38 (17.0)	13 (13.0)	25 (20.2)	
Alcohol consumption during pregnancy ^c				
No	150 (67.0)	69 (69.0)	81 (65.3)	0.561
Yes	74 (33.0)	31 (31.0)	43 (34.7)	
Parity ^c				
Primiparous	116 (51.8)	49 (49.0)	67 (54.0)	0.454
Multiparous	108 (48.2)	51 (51.0)	57 (46.0)	
Annual household income (million Japanese yen) ^c				
< 5	154 (68.8)	71 (71.0)	83 (66.9)	0.784
≥ 5	68 (30.4)	28 (28.0)	40 (32.3)	
Missing data	2 (0.9)	1 (1.0)	1 (0.8)	
Maternal blood sampling period ^c				
During pregnancy	153 (68.3)	65 (65.0)	88 (71.0)	0.340
After birth	71 (31.7)	35 (35.0)	36 (29.0)	
Infant sex ^c				
Male	100 (44.6)	100 (100.0)	0 (0.0)	(-)
Female	124 (55.4)	0 (0.0)	124 (100.0)	
Gestational age (weeks) ^b	39.3 ± 1.0	39.2 ± 1.0	39.4 ± 1.1	0.310
Infant birth weight (g) ^b	3,121.9 ± 332.7	3,173.4 ± 306.2	3,080.4 ± 348.4	0.037
Maternal serum levels				
PFOS (ng/mL) ^d	5.0 (3.3, 6.9)	5.1 (3.7, 7.0)	4.8 (3.2, 6.8)	0.417
PFOA (ng/mL) ^d	1.4 (0.9, 2.0)	1.5 (0.9, 2.1)	1.3 (0.8, 1.8)	0.095
Cord serum levels				
P ₄ (ng/mL) ^d	217.8 (173.9, 282.4)	228.8 (179.1, 298.7)	206.6 (164.5, 277.7)	0.184
DHEA (ng/mL) ^d	2.3 (1.8, 3.0)	2.1 (1.6, 2.8)	2.4 (2.0, 3.3)	0.002
A-dione (ng/mL) ^d	0.45 (0.36, 0.57)	0.46 (0.36, 0.57)	0.45 (0.36, 0.57)	0.916
DHEA/A-dione ^d	4.8 (3.7, 6.0)	4.2 (3.4, 5.6)	5.0 (4.0, 6.3)	0.003
T (pg/mL) ^d	84.4 (59.5, 111.2)	92.9 (71.0, 117.0)	73.1 (52.9, 99.5)	<0.001
E ₂ (ng/mL) ^d	4.8 (3.3, 7.1)	4.7 (3.3, 7.6)	4.8 (3.4, 6.6)	0.458
T/E ₂ ^d	17.0 (12.1, 22.5)	17.9 (12.9, 25.5)	16.1 (11.9, 21.5)	0.058

2 ^a Males vs. Females analyzed using the χ^2 -test, independent *t*-test, and Mann-Whitney *U*-test.

1 ^b Mean \pm standard deviation (SD).

2 ^c n (%).

3 ^d Median (inter-quartile range).

4

1 Table 2. Fetal genotype frequencies

Gene name, genotype	n (%)	HWE	Gene name, genotype	n (%)	HWE
<i>CYP17A1</i> (A>G, dbSNP ID: rs743572)			<i>HSD3B2</i> (A>T, dbSNP ID: rs2854964)		
AA	65 (29.0)	$\chi^2 = 2.122$	AA	142 (63.4)	$\chi^2 = 2.173$
AG	101 (45.1)	$p = 0.145$	AT	68 (30.4)	$p = 0.140$
GG	58 (25.9)		TT	14 (6.3)	
<i>CYP19A1</i> (G>A, dbSNP ID: rs10046)			<i>HSD3B2</i> (C>T, dbSNP ID: rs4659175)		
GG	67 (29.9)	$\chi^2 = 1.456$	CC	141 (62.9)	$\chi^2 = 0.210$
GA	119 (53.1)	$p = 0.228$	CT	72 (32.1)	$p = 0.646$
AA	38 (17.0)		TT	11 (4.9)	
<i>CYP19A1</i> (C>T, dbSNP ID: rs700519)			<i>HSD17B1</i> (G>A, dbSNP ID: rs605059)		
CC	138 (61.6)	$\chi^2 = 1.197$	GG	64 (28.6)	$\chi^2 = 0.651$
CT	72 (32.1)	$p = 0.274$	GA	117 (52.2)	$p = 0.420$
TT	14 (6.3)		AA	43 (19.2)	
<i>CYP19A1</i> (A>C, dbSNP ID: rs727479)			<i>HSD17B1</i> (C>A, dbSNP ID: rs676387)		
AA	99 (44.2)	$\chi^2 = 0.885$	CC	67 (29.9)	$\chi^2 = 0.557$
AC	95 (42.4)	$p = 0.347$	CA	116 (51.8)	$p = 0.456$
CC	30 (13.4)		AA	41 (18.3)	
<i>HSD3B1</i> (T>C, dbSNP ID: rs6203)			<i>HSD17B1</i> (C>A, dbSNP ID: rs2676531)		
TT	104 (46.4)	$\chi^2 = 0.069$	CC	63 (28.1)	$\chi^2 = 1.159$
TC	96 (42.9)	$p = 0.793$	CT	119 (53.1)	$p = 0.282$
CC	24 (10.7)		TT	42 (18.8)	
<i>HSD3B2</i> (C>T, dbSNP ID: rs1819698)			<i>HSD17B3</i> (T>C, dbSNP ID: rs4743709)		
CC	85 (37.9)	$\chi^2 = 0.720$	TT	117 (52.2)	$\chi^2 = 2.445$
CT	101 (45.1)	$p = 0.396$	TC	96 (42.9)	$p = 0.118$
TT	38 (17.0)		CC	11 (4.9)	

- 2 Abbreviations: *CYP17A1*, cytochrome P450 17A1; *CYP19A1*, cytochrome P450 19A1; *HSD3B1*, 3 β -hydroxysteroid dehydrogenase type 1;
- 3 *HSD3B2*, 3 β -hydroxysteroid dehydrogenase type 2; *HSD17B1*, 17 β -hydroxysteroid dehydrogenase type 1, and *HSD17B3*, 17 β -hydroxysteroid
- 4 dehydrogenase type 3; HWE, Hardy-Weinberg equilibrium; SNP, single nucleotide polymorphism.
- 5 Chi-squared test was employed to test whether the frequency of genotype distribution conformed to the Hardy-Weinberg equilibrium.
- 6

1 Table 3. Associations between perfluorooctanesulfonic acid (PFOS) or perfluorooctanoic acid (PFOA) levels in maternal sera during pregnancy and infant sex hormone levels in cord sera

Outcome	Total (n = 224)				Males (n = 100)				Females (n = 124)			
	Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value	Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value	Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value
Exposure: PFOS (ng/mL)												
P ₄ (ng/mL)	-0.311 (-0.499, -0.124)	0.001	-0.400 (-0.598, -0.201)	<0.001	-0.223 (-0.459, 0.013)	0.063	-0.270 (-0.512, -0.029)	0.029	-0.401 (-0.684, -0.118)	0.006	-0.517 (-0.829, -0.205)	0.001
DHEA (ng/mL)	0.315 (0.134, 0.496)	0.001	0.359 (0.167, 0.552)	<0.001	0.252 (0.027, 0.477)	0.029	0.249 (0.015, 0.483)	0.037	0.393 (0.124, 0.663)	0.005	0.448 (0.146, 0.751)	0.004
A-dione (ng/mL)	-0.013 (-0.148, 0.122)	0.852	0.022 (-0.123, 0.167)	0.767	-0.056 (-0.243, 0.131)	0.555	-0.049 (-0.239, 0.142)	0.614	0.025 (-0.170, 0.221)	0.798	0.077 (-0.141, 0.296)	0.485
DHEA/A-dione	0.328 (0.116, 0.540)	0.003	0.338 (0.110, 0.565)	0.004	0.308 (0.046, 0.570)	0.022	0.298 (0.026, 0.569)	0.032	0.368 (0.048, 0.688)	0.025	0.371 (0.012, 0.730)	0.043
T (pg/mL)	-0.049 (-0.227, 0.128)	0.585	0.007 (-0.180, 0.194)	0.945	-0.142 (-0.373, 0.088)	0.223	-0.091 (-0.334, 0.151)	0.457	0.007 (-0.253, 0.267)	0.958	0.096 (-0.194, 0.385)	0.514
E ₂ (ng/mL)	0.217 (0.065, 0.369)	0.005	0.166 (0.005, 0.326)	0.044	0.272 (0.035, 0.508)	0.025	0.213 (-0.031, 0.458)	0.087	0.164 (-0.037, 0.365)	0.108	0.121 (-0.102, 0.343)	0.284
T/E ₂	-0.266 (-0.417, -0.115)	0.001	-0.159 (-0.313, -0.005)	0.043	-0.414 (-0.614, -0.214)	<0.001	-0.305 (-0.497, -0.112)	0.002	-0.157 (-0.377, 0.062)	0.159	-0.025 (-0.263, 0.212)	0.833
Exposure: PFOA (ng/mL)												
P ₄ (ng/mL)	0.174 (0.025, 0.323)	0.023	0.160 (-0.018, 0.338)	0.077	0.174 (-0.024, 0.373)	0.085	0.216 (-0.026, 0.457)	0.080	0.156 (-0.062, 0.374)	0.159	0.111 (-0.151, 0.374)	0.402
DHEA (ng/mL)	-0.121 (-0.267, 0.024)	0.101	-0.161 (-0.332, 0.010)	0.065	-0.011 (-0.205, 0.183)	0.911	-0.036 (-0.274, 0.201)	0.763	-0.162 (-0.370, 0.046)	0.126	-0.202 (-0.452, 0.049)	0.114
A-dione (ng/mL)	-0.056 (-0.161, 0.050)	0.302	-0.064 (-0.190, 0.062)	0.318	-0.018 (-0.175, 0.140)	0.823	0.019 (-0.171, 0.208)	0.844	-0.079 (-0.225, 0.068)	0.289	-0.096 (-0.272, 0.080)	0.280
DHEA/A-dione	-0.066 (-0.235, 0.104)	0.446	-0.097 (-0.298, 0.104)	0.343	0.007 (-0.219, 0.233)	0.953	-0.055 (-0.331, 0.221)	0.694	-0.083 (-0.329, 0.163)	0.505	-0.105 (-0.400, 0.189)	0.481
T (pg/mL)	-0.004 (-0.143, 0.136)	0.959	0.013 (-0.150, 0.176)	0.877	-0.075 (-0.270, 0.119)	0.443	0.028 (-0.213, 0.269)	0.817	0.013 (-0.183, 0.209)	0.899	0.014 (-0.220, 0.248)	0.904
E ₂ (ng/mL)	0.097 (-0.024, 0.218)	0.117	0.004 (-0.137, 0.145)	0.954	0.133 (-0.069, 0.335)	0.194	0.034 (-0.212, 0.281)	0.782	0.062 (-0.090, 0.215)	0.422	-0.014 (-0.195, 0.166)	0.877
T/E ₂	-0.100 (-0.222, 0.021)	0.105	0.009 (-0.127, 0.144)	0.900	-0.209 (-0.386, -0.032)	0.021	-0.006 (-0.207, 0.195)	0.950	-0.050 (-0.216, 0.117)	0.557	0.028 (-0.163, 0.220)	0.770

2 Associations between maternal PFOS or PFOA levels and infant sex hormone levels were evaluated using multiple linear regression models.

3 ^a Crude: Non-adjusted.

4 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household income (< 5/≥ 5 million Japanese yen),
5 parity (primipara/multipara), infant sex (male/female; only all participants), maternal blood sampling periods (during pregnancy or after birth), and infant birth weight (grams; continuous).

6 β (95% CI) represents change (95% confidence intervals) in log₁₀-transformed P₄ (ng/mL), DHEA (ng/mL), A-dione (ng/mL), DHEA/A-dione, T (pg/mL), E₂ (ng/mL), or T/E₂ levels for each 10-fold PFOS or PFOA level
7 (ng/mL).

1 Table 4. Associations between PFOS levels in maternal sera during pregnancy and infant
 2 genotypes *CYP17A1* (rs743572) on sex hormone levels in cord sera in female infants

Outcome	Exposure/Genotype	Females (n = 124)			
		Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value
P ₄ (ng/mL)	PFOS (ng/mL)	-0.316 (-0.811, 0.178)	0.207	-0.392 (-0.894, 0.111)	0.126
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.045 (-0.405, 0.495)	0.842	0.095 (-0.361, 0.552)	0.680
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.162 (-0.770, 0.445)	0.598	-0.218 (-0.831, 0.394)	0.482
DHEA (ng/mL)	PFOS (ng/mL)	0.481 (0.008, 0.953)	0.046	0.512 (0.023, 1.002)	0.040
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.121 (-0.309, 0.551)	0.579	0.103 (-0.342, 0.547)	0.648
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.110 (-0.691, 0.470)	0.707	-0.084 (-0.680, 0.513)	0.782
A-dione (ng/mL)	PFOS (ng/mL)	0.402 (0.071, 0.734)	0.018	0.445 (0.102, 0.787)	0.012
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.390 (0.087, 0.692)	0.012	0.396 (0.084, 0.707)	0.013
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.579 (-0.987, -0.171)	0.006	-0.579 (-0.997, -0.161)	0.007
DHEA/A-dione	PFOS (ng/mL)	0.078 (-0.478, 0.634)	0.781	0.068 (-0.508, 0.643)	0.816
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	-0.269 (-0.775, 0.238)	0.295	-0.293 (-0.815, 0.229)	0.269
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	0.469 (-0.215, 1.153)	0.177	0.495 (-0.206, 1.196)	0.164
T (pg/mL)	PFOS (ng/mL)	0.578 (0.139, 1.016)	0.010	0.641 (0.191, 1.091)	0.006
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.601 (0.202, 1.000)	0.003	0.595 (0.186, 1.003)	0.005
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.868 (-1.407, -0.329)	0.002	-0.856 (-1.404, -0.307)	0.003
E ₂ (ng/mL)	PFOS (ng/mL)	0.388 (0.040, 0.736)	0.029	0.359 (0.004, 0.714)	0.048
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.213 (-0.103, 0.530)	0.185	0.243 (-0.080, 0.565)	0.139
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.358 (-0.786, 0.070)	0.100	-0.383 (-0.815, 0.050)	0.083
T/E ₂	PFOS (ng/mL)	0.190 (-0.188, 0.567)	0.322	0.282 (-0.096, 0.659)	0.142
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.388 (0.044, 0.731)	0.027	0.352 (0.009, 0.695)	0.044
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.510 (-0.975, -0.046)	0.032	-0.473 (-0.933, -0.013)	0.044

3 Associations between maternal PFOS levels and infant genotypes on sex hormone levels were
 4 evaluated using multiple linear regression models.

5 ^a Crude: Non-adjusted.

6 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third
 7 trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household
 8 income (< 5/≥ 5 million Japanese yen), parity (primipara/multipara), infant sex (male/female; all
 9 participants), maternal blood sampling periods (during pregnancy or after birth), and infant birth
 10 weight (grams; continuous).

11 β (95% CI) represents change (95% confidence intervals) in log₁₀-transformed A-dione (ng/mL),
 12 T (pg/mL), E₂ (ng/mL), or DHEA/A-dione levels for each 10-fold PFOS level (ng/mL).

13 PFOS-*CYP17A1* (rs743572) interaction term was defined as “log₁₀-transformed PFOS levels
 14 (continuous) * genotype (0 = AA and 1 =AG/GG)”.

15

1 Table 5. PFOS levels in maternal sera and sex steroid hormone levels in cord sera stratified by
 2 female infant genotypes *CYP17A1* (rs743572)

Outcome	<i>CYP17A1</i> (rs743572) Infant genotype	Exposure: PFOS (ng/mL) Females (<i>n</i> = 124)			
		Crude ^a β (95% CI)	<i>p</i> value	Adjusted ^b β (95% CI)	<i>p</i> value
P ₄ (ng/mL)	AA	-0.316 (-0.892, 0.259)	0.271	-0.513 (-1.124, 0.097)	0.096
	AG/GG	-0.479 (-0.816, -0.142)	0.006	-0.558 (-0.929, -0.186)	0.004
DHEA (ng/mL)	AA	0.481 (-0.018, 0.979)	0.058	0.588 (0.024, 1.152)	0.042
	AG/GG	0.370 (0.034, 0.706)	0.031	0.379 (-0.002, 0.761)	0.051
A-dione (ng/mL)	AA	0.402 (0.025, 0.780)	0.038	0.494 (0.059, 0.930)	0.028
	AG/GG	-0.177 (-0.405, 0.052)	0.128	-0.157 (-0.419, 0.104)	0.235
DHEA/A-dione	AA	0.078 (-0.413, 0.570)	0.748	0.093 (-0.461, 0.647)	0.731
	AG/GG	0.547 (0.128, 0.965)	0.011	0.536 (0.065, 1.008)	0.026
T (pg/mL)	AA	0.578 (0.126, 1.029)	0.014	0.679 (0.176, 1.181)	0.010
	AG/GG	-0.290 (-0.605, 0.025)	0.071	-0.198 (-0.554, 0.157)	0.271
E ₂ (ng/mL)	AA	0.388 (-0.014, 0.790)	0.058	0.360 (-0.117, 0.838)	0.132
	AG/GG	0.030 (-0.208, 0.268)	0.801	-0.017 (-0.285, 0.251)	0.900
T/E ₂	AA	0.190 (-0.200, 0.580)	0.330	0.318 (-0.099, 0.735)	0.128
	AG/GG	-0.320 (-0.591, -0.049)	0.021	-0.181 (-0.485, 0.122)	0.239

3 Associations between maternal PFOS and sex hormone levels were evaluated using multiple
 4 linear regression models.

5 ^a Crude: Non-adjusted.

6 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third
 7 trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household
 8 income (< 5/≥ 5 million Japanese yen), parity (primipara/multipara), infant sex (male/female; all
 9 participants), maternal blood sampling periods (during pregnancy or after birth), and infant birth
 10 weight (grams; continuous).

11 β (95% CI) represents change (95% confidence intervals) in log₁₀-transformed P₄ (ng/mL),

12 DHEA (ng/mL), A-dione (ng/mL), DHEA/A-dione, T (pg/mL), E₂ (ng/mL), or T/E₂ levels per

13 10-fold increase in maternal PFOS levels.

14

15

Supplementary Material

Associations among maternal perfluoroalkyl substance levels, fetal sex-hormone enzymatic gene polymorphisms, and fetal sex hormone levels in the Hokkaido study

Sumitaka Kobayashi, Fumihiro Sata, Atsuko Araki, Chihiro Miyashita, Sachiko Itoh, Houman Goudarzi, Yusuke Iwasaki, Takahiko Mitsui, Kimihiko Moriya, Nobuo Shinohara, Kazutoshi Cho, Reiko Kishi

Contents

- Supplementary Methods

1. Pre-amplification for high-throughput PCR sequencing

2. High-throughput real-time PCR using dynamic chips

3. TaqMan real-time PCR

- Supplementary Table 1. PFAS levels during pregnancy of included participants ($n = 224$) and excluded participants ($n = 223$)

- Supplementary Table 2. Spearman's rank correlation coefficients between maternal gestational weeks for blood sample collection and PFOS, PFOA, and sex hormone levels

- Supplementary Table 3. Sensitive analysis of associations between perfluorooctanesulfonic acid (PFOS) or perfluorooctanoic acid (PFOA) levels in maternal sera during pregnancy and infant sex hormone levels in the cord sera among pregnant women and infant pairs for which maternal blood samples were obtained before delivery

- Supplementary Table 4. Associations between PFOS or PFOA levels in maternal sera during pregnancy and infant sex on sex hormone levels in cord sera

- Supplementary Table 5. Sensitivity analysis of associations between PFOS or PFOA levels in

- 1 maternal sera during pregnancy and infant sex on sex hormone levels in cord sera among
2 pregnant women and infant pairs for which maternal blood samples were obtained before
3 delivery
- 4 ● Supplementary Table 6. Sensitivity analysis of associations between PFOS levels in
5 maternal sera during pregnancy and female infant genotypes *CYP17A1* (rs743572) on sex
6 hormone levels in cord sera among pregnant women and female infant pairs for which
7 maternal blood samples were obtained before delivery
- 8 ● Supplementary Table 7. Sensitivity analysis of PFOS levels in maternal sera and sex steroid
9 hormone levels in cord sera stratified by female infant genotypes *CYP17A1* (rs743572)
10 among pregnant women and female infant pairs for which maternal blood samples were
11 obtained before delivery
- 12 ● Supplementary Table 8. Association of infant genotype *CYP17A1* (rs743572) with PFOS
13 and PFOA levels in maternal blood and sex hormone levels in cord blood
14

1 **Supplementary Methods:**

2 ***1. Pre-amplification for high-throughput PCR sequencing***

3 Pre-amplification was performed on each sample using Qiagen 2× Multiplex PCR Master Mix
4 according to the manufacturer's protocol (Qiagen GmbH, Hilden, Germany; Fluidigm Corp.,
5 South San Francisco, CA, USA) to increase the amount of available template, including 96 assays
6 used in this system. The mixture (final volume 5.0 μL) consisted of 2.5 μL Qiagen 2× Multiplex
7 PCR master mix, 0.5 μL of 10× SNP type-specific target amplification (STA) primer pool,
8 comprising 96 μL/100 μM each of SNP-type assay STA primer and LSP, and 208.0 μL of DNA
9 suspension buffer (TEKnova, Hollister, CA, USA), 1.25 μL genome DNA, and water. Pre-
10 amplifications were conducted in a Verity 96-well Thermal Cycler (Applied Biosystems, Foster
11 City, CA, USA) according to the following protocol: initial denaturation at 95°C for 15 min; 14
12 cycles of 15 s at 95°C and 4 min at 60°C. Each pre-amplification product was diluted 100× before
13 use as a template in the subsequent PCR reactions.

14

15 ***2. High-throughput real-time PCR using dynamic chips***

16 Fluidigm 96.96 real-time PCR was performed according to the manufacturer's instructions
17 (Fluidigm Corp., South San Francisco, CA, USA). Sample and assay mixtures were prepared
18 separately. Each sample mixture (final volume: 6.0 μL) consisted of 3.0 μL of the Biotium 2× fast
19 probe master mix (Biotium Inc., Fremont, CA, USA), 0.3 μL of the 20× SNP type sample loading
20 reagent (Fluidigm Corp.), 0.1 μL of the 60× SNP type reagent (Fluidigm Corp.), 0.036 μL of the
21 50× ROX solution (Invitrogen, Waltham, MA, US), 0.064 μL of water, and 2.5 μL of the diluted
22 pre-amplification product as the template. The assay mixture for each sample (final volume 5.0
23 μL) consisted of 2.5 μL of the 2× assay loading reagent (Fluidigm Corp.), 1.5 μL of water, and
24 1.0 μL of the SNP type assay mix, comprising 3.0 μL of the SNP type assay ASP1/ASP2 (Fluidigm
25 Corp.), 8.0 μL of the SNP type assay LSP (Fluidigm Corp.), and 29.0 μL of the DNA suspension
26 buffer (TEKnova). The assay (5 μL) and the sample (6 μL) were added to each assay and sample

1 inlet, respectively, and were loaded into separate reaction chambers on a 96.96 Dynamic Array
2 IFC chip (Fluidigm Corp.) on an IFC controller HX (Fluidigm Corp.). The protocol was as
3 follows: 95°C initial denaturation for 5 min; 1 cycle of 15 s at 95°C, 45 s at 64°C, and 15 s at
4 72°C; 1 cycle of 15 s at 95°C, 45 s at 63°C, and 15 s at 72°C; 1 cycle of 15 s at 95°C, 45 s at 62°C,
5 and 15 s at 72°C; 1 cycle of 15 s at 95°C, 45 s at 61°C, and 15 s at 72°C; and 34 cycles of 15 s at
6 95°C, 45 s at 60°C, and 15 s at 72°C using the FC1 cycler (Fluidigm Corp.). Fluorescence was
7 measured using an EP1 reader (Fluidigm Corp.) coupled to the SNP genotyping analytical
8 software v.3.0.2. (Fluidigm Corp.). Only the infant genotypes that were successfully tested in
9 duplicate were used.

10

11 **3. *TaqMan real-time PCR***

12 Five genotyping experiments were performed using the StepOne real-time PCR system (Applied
13 Biosystems) and a fluorogenic 5'-nuclease assay with TaqMan minor groove binder probes
14 (Applied Biosystems) according to the manufacturer's protocol. Each reaction mixture (final
15 volume: 10 µL) consisted of 2 ng/µL of the genomic DNA, TaqMan Assay on-Demand SNP
16 genotyping assay mix (Applied Biosystems), TaqMan GTXpress Master Mix (Applied
17 Biosystems), and No AmpErase UNG (Applied Biosystems). The reaction conditions were 20 s
18 at 95.0°C, 40 cycles of 3 s at 95°C, and 20 s at 60°C. Allelic discrimination was determined by
19 measuring the relative dye fluorescence at 60°C. Only infant genotypes that were successfully
20 tested in duplicates were used.

21

22

1 Supplementary Table 1. PFAS levels during pregnancy of included participants ($n = 224$) and
 2 excluded participants ($n = 223$)

	Included participants ($n = 224$)	Excluded participants ($n = 223$)	p value
Maternal serum levels			
PFOS (ng/mL)	5.0 (3.3, 6.9)	5.5 (3.6, 7.2)	0.174
PFOA (ng/mL)	1.4 (0.9, 2.0)	1.2 (0.8, 1.6)	0.003

3 Median (inter-quartile range).

4 Mann-Whitney's U -test.

5

1 Supplementary Table 2. Spearman's rank correlation coefficients between maternal gestational
 2 weeks for blood sample collection and PFOS, PFOA, and sex hormone levels

	Gestational weeks at blood sample collection (weeks)	
	Spearman's ρ	p value
PFOS (ng/mL)	0.046	0.497
PFOA (ng/mL)	0.075	0.266
P ₄ (ng/mL)	0.011	0.871
DHEA (ng/mL)	0.056	0.408
A-dione (ng/mL)	0.068	0.309
DHEA/A-dione	-0.042	0.536
T (pg/mL)	-0.058	0.386
E ₂ (ng/mL)	0.041	0.543
T/E ₂	-0.081	0.229

3

4

1 Supplementary Table 3. Sensitivity analysis of associations between perfluorooctanesulfonic acid (PFOS) or perfluorooctanoic acid (PFOA) levels in maternal sera during pregnancy and infant sex hormone levels in cord sera
 2 among pregnant women and infant pairs for which maternal blood samples were obtained before delivery

Outcome	Total (n = 153)				Males (n = 65)				Females (n = 88)			
	Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value	Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value	Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value
Exposure: PFOS (ng/mL)												
P ₄ (ng/mL)	-0.376 (-0.612, -0.141)	0.002	-0.463 (-0.709, -0.217)	<0.001	-0.263 (-0.572, 0.046)	0.094	-0.301 (-0.644, 0.042)	0.084	-0.479 (-0.809, -0.148)	0.005	-0.542 (-0.897, -0.187)	0.003
DHEA (ng/mL)	0.361 (0.135, 0.587)	0.002	0.440 (0.208, 0.672)	<0.001	0.386 (0.104, 0.668)	0.008	0.450 (0.163, 0.736)	0.003	0.394 (0.078, 0.711)	0.015	0.433 (0.087, 0.780)	0.015
A-dione (ng/mL)	-0.074 (-0.237, 0.090)	0.373	-0.024 (-0.198, 0.149)	0.781	-0.038 (-0.283, 0.207)	0.757	-0.016 (-0.275, 0.244)	0.905	-0.095 (-0.319, 0.129)	0.400	-0.048 (-0.290, 0.195)	0.697
DHEA/A-dione	0.435 (0.160, 0.709)	0.002	0.465 (0.177, 0.753)	0.002	0.424 (0.078, 0.770)	0.017	0.465 (0.083, 0.848)	0.018	0.490 (0.101, 0.878)	0.014	0.481 (0.057, 0.906)	0.027
T (pg/mL)	-0.044 (-0.262, 0.174)	0.692	-0.015 (-0.245, 0.215)	0.896	-0.011 (-0.328, 0.305)	0.944	0.042 (-0.312, 0.396)	0.813	-0.092 (-0.389, 0.206)	0.542	-0.035 (-0.358, 0.288)	0.829
E ₂ (ng/mL)	0.207 (0.032, 0.381)	0.020	0.192 (0.008, 0.375)	0.040	0.412 (0.126, 0.699)	0.005	0.386 (0.076, 0.695)	0.016	0.077 (-0.144, 0.298)	0.490	0.074 (-0.162, 0.310)	0.536
T/E ₂	-0.251 (-0.441, -0.060)	0.010	-0.207 (-0.400, -0.013)	0.036	-0.423 (-0.668, -0.178)	0.001	-0.344 (-0.594, -0.093)	0.008	-0.169 (-0.442, 0.104)	0.222	-0.109 (-0.395, 0.178)	0.452
Exposure: PFOA (ng/mL)												
P ₄ (ng/mL)	0.104 (-0.079, 0.286)	0.263	0.053 (-0.158, 0.264)	0.621	0.167 (-0.091, 0.425)	0.200	0.235 (-0.079, 0.549)	0.140	0.022 (-0.232, 0.374)	0.861	-0.033 (-0.330, 0.265)	0.827
DHEA (ng/mL)	-0.128 (-0.303, 0.046)	0.149	-0.124 (-0.322, 0.075)	0.220	-0.106 (-0.351, 0.139)	0.391	-0.089 (-0.370, 0.192)	0.529	-0.068 (-0.308, 0.173)	0.578	-0.111 (-0.395, 0.174)	0.441
A-dione (ng/mL)	-0.060 (-0.183, 0.063)	0.336	-0.052 (-0.194, 0.090)	0.468	-0.023 (-0.226, 0.179)	0.819	0.082 (-0.153, 0.317)	0.486	-0.080 (-0.245, 0.084)	0.334	-0.086 (-0.278, 0.106)	0.377
DHEA/A-dione	-0.068 (-0.281, 0.145)	0.527	-0.071 (-0.316, 0.173)	0.564	-0.083 (-0.381, 0.216)	0.582	-0.171 (-0.534, 0.191)	0.348	0.013 (-0.283, 0.309)	0.931	-0.025 (-0.372, 0.322)	0.886
T (pg/mL)	0.020 (-0.145, 0.185)	0.810	0.013 (-0.176, 0.202)	0.889	-0.038 (-0.300, 0.223)	0.770	0.035 (-0.287, 0.356)	0.829	-0.002 (-0.221, 0.218)	0.988	0.010 (-0.247, 0.256)	0.940
E ₂ (ng/mL)	0.043 (-0.091, 0.176)	0.530	-0.012 (-0.165, 0.141)	0.877	0.122 (-0.128, 0.372)	0.334	0.090 (-0.206, 0.385)	0.545	-0.014 (-0.177, 0.150)	0.869	-0.045 (-0.232, 0.143)	0.635
T/E ₂	-0.023 (-0.169, 0.124)	0.762	0.025 (-0.136, 0.186)	0.756	-0.160 (-0.378, 0.057)	0.145	-0.055 (-0.297, 0.187)	0.651	0.012 (-0.191, 0.214)	0.908	0.055 (-0.173, 0.282)	0.635

3 Associations between maternal PFOS or PFOA levels and infant sex hormone levels were evaluated using multiple linear regression models.

4 ^a Crude: Non-adjusted.

5 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household income (< 5/≥ 5 million Japanese yen),
 6 parity (primipara/multipara), infant sex (male/female; only all participants), maternal blood sampling periods (during pregnancy or after birth), and infant birth weight (grams; continuous).

7 β (95% CI) represents change (95% confidence intervals) in log₁₀-transformed P₄ (ng/mL), DHEA (ng/mL), A-dione (ng/mL), DHEA/A-dione, T (pg/mL), E₂ (ng/mL), or T/E₂ levels for each 10-fold PFOS or PFOA level
 8 (ng/mL).

9
 10
 11

1 Supplementary Table 4. Associations between PFOS or PFOA levels in maternal sera during
2 pregnancy and infant sex on sex hormone levels in cord sera

Outcome	Exposure/Infant sex	Total (n = 224)			
		Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value
P ₄ (ng/mL)	PFOS	-0.223 (-0.501, 0.054)	0.115	-0.301 (-0.583, -0.019)	0.037
	Females (vs. Males)	0.049 (-0.222, 0.319)	0.723	0.044 (-0.226, 0.190)	0.747
	PFOS × Sex (Interaction term)	-0.178 (-0.554, 0.198)	0.353	-0.186 (-0.562, 0.190)	0.331
DHEA (ng/mL)	PFOS	0.252 (-0.013, 0.517)	0.062	0.269 (-0.004, 0.543)	0.054
	Females (vs. Males)	0.022 (-0.236, 0.280)	0.869	0.004 (-0.258, 0.266)	0.975
	PFOS × Sex (Interaction term)	0.141 (-0.217, 0.500)	0.438	0.169 (-0.196, 0.534)	0.361
A-dione (ng/mL)	PFOS	0.056 (-0.257, 0.145)	0.585	-0.041 (-0.247, 0.166)	0.698
	Females (vs. Males)	-0.046 (-0.241, 0.150)	0.647	-0.063 (-0.261, 0.135)	0.531
	PFOS × Sex (Interaction term)	0.081 (-0.191, 0.353)	0.558	0.117 (-0.158, 0.392)	0.402
DHEA/A-dione	PFOS	0.308 (-0.005, 0.620)	0.053	0.310 (-0.014, 0.633)	0.061
	Females (vs. Males)	0.067 (-0.237, 0.372)	0.664	0.067 (-0.243, 0.377)	0.671
	PFOS × Sex (Interaction term)	0.060 (-0.363, 0.483)	0.779	0.052 (-0.380, 0.484)	0.812
T (pg/mL)	PFOS	-0.142 (-0.403, 0.118)	0.283	-0.096 (-0.362, 0.169)	0.476
	Females (vs. Males)	-0.202 (-0.455, 0.052)	0.119	-0.218 (-0.473, 0.037)	0.093
	PFOS × Sex (Interaction term)	0.149 (-0.204, 0.502)	0.406	0.193 (-0.161, 0.548)	0.284
E ₂ (ng/mL)	PFOS	0.272 (0.046, 0.498)	0.019	0.220 (-0.008, 0.449)	0.059
	Females (vs. Males)	0.042 (-0.178, 0.262)	0.706	0.031 (-0.189, 0.250)	0.784
	PFOS × Sex (Interaction term)	-0.108 (-0.414, 0.199)	0.489	-0.103 (-0.408, 0.202)	0.506
T/E ₂	PFOS	-0.412 (-0.636, -0.192)	<0.001	-0.317 (-0.534, -0.100)	0.004
	Females (vs. Males)	-0.244 (-0.460, -0.027)	0.027	-0.249 (-0.457, -0.041)	0.019
	PFOS × Sex (Interaction term)	0.257 (-0.044, 0.558)	0.094	0.296 (0.007, 0.586)	0.045
P ₄ (ng/mL)	PFOA	0.174 (-0.063, 0.412)	0.149	0.169 (-0.095, 0.432)	0.208
	Females (vs. Males)	-0.053 (-0.145, 0.038)	0.251	-0.052 (-0.147, 0.043)	0.280
	PFOA × Sex (Interaction term)	-0.018 (-0.325, 0.288)	0.907	-0.015 (-0.331, 0.301)	0.927
DHEA (ng/mL)	PFOA	-0.011 (-0.239, 0.217)	0.924	-0.069 (-0.323, 0.184)	0.591
	Females (vs. Males)	0.121 (0.033, 0.209)	0.007	0.109 (0.018, 0.201)	0.020
	PFOA × Sex (Interaction term)	-0.151 (-0.445, 0.144)	0.314	-0.149 (-0.454, 0.155)	0.334
A-dione (ng/mL)	PFOA	-0.018 (-0.186, 0.151)	0.836	-0.018 (-0.204, 0.169)	0.853
	Females (vs. Males)	0.014 (-0.052, 0.079)	0.682	0.020 (-0.048, 0.087)	0.569
	PFOA × Sex (Interaction term)	-0.061 (-0.279, 0.157)	0.582	-0.075 (-0.299, 0.148)	0.507
DHEA/A-dione	PFOA	0.007 (-0.261, 0.275)	0.960	-0.052 (-0.350, 0.247)	0.734
	Females (vs. Males)	0.107 (0.004, 0.211)	0.042	0.090 (-0.018, 0.197)	0.102
	PFOA × Sex (Interaction term)	-0.090 (-0.437, 0.257)	0.610	-0.074 (-0.432, 0.284)	0.684
T (pg/mL)	PFOA	-0.075 (-0.295, 0.144)	0.498	-0.017 (-0.259, 0.224)	0.887
	Females (vs. Males)	-0.109 (-0.194, -0.025)	0.012	-0.091 (-0.178, -0.004)	0.041
	PFOA × Sex (Interaction term)	0.088 (-0.195, 0.371)	0.541	0.049 (-0.240, 0.339)	0.738
E ₂ (ng/mL)	PFOA	0.133 (-0.059, 0.326)	0.173	0.046 (-0.163, 0.256)	0.664
	Females (vs. Males)	-0.023 (-0.097, 0.051)	0.540	-0.038 (-0.114, 0.037)	0.317
	PFOA × Sex (Interaction term)	-0.071 (-0.320, 0.177)	0.573	-0.068 (-0.319, 0.183)	0.592
T/E ₂	PFOA	-0.209 (-0.400, -0.018)	0.032	-0.064 (-0.264, 0.137)	0.532
	Females (vs. Males)	-0.086 (-0.160, -0.012)	0.022	-0.053 (-0.125, 0.020)	0.152
	PFOA × Sex (Interaction term)	0.159 (-0.088, 0.406)	0.205	0.118 (-0.122, 0.358)	0.335

3 Associations between maternal PFOS or PFOA levels and infant sex on sex hormone levels were
4 evaluated using multiple linear regression models.

5 ^a Crude: Non-adjusted.

6 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third
7 trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household

1 income (< 5/≥ 5 million Japanese yen), parity (primipara/multipara), maternal blood sampling
2 periods (during pregnancy or after birth), and infant birth weight (grams; continuous).
3 β (95% CI) represents change (95% confidence intervals) in log₁₀-transformed A-dione (ng/mL),
4 T (pg/mL), E₂ (ng/mL), or DHEA/A-dione levels for each 10-fold PFOS or PFOA level
5 (ng/mL).
6 PFAS-sex interaction term was defined as “log₁₀-transformed PFOS or PFOA levels
7 (continuous) * sex (0 = males and 1 = females)”.
8

1 Supplementary Table 5. Sensitivity analysis of associations between PFOS or PFOA levels in
 2 maternal sera during pregnancy and infant sex on sex hormone levels in cord sera among pregnant
 3 women and infant pairs for which maternal blood samples were obtained before delivery

Outcome	Exposure/Infant sex	Total (n = 153)			
		Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value
P ₄ (ng/mL)	PFOS	-0.263 (-0.646, 0.120)	0.177	-0.337 (-0.732, 0.058)	0.094
	Females (vs. Males)	0.024 (-0.332, 0.381)	0.894	0.013 (-0.349, 0.375)	0.945
	PFOS × Sex (Interaction term)	-0.216 (-0.697, 0.266)	0.378	-0.200 (-0.690, 0.290)	0.421
DHEA (ng/mL)	PFOS	0.386 (0.023, 0.748)	0.037	0.410 (0.036, 0.783)	0.032
	Females (vs. Males)	0.163 (-0.175, 0.500)	0.342	0.131 (-0.211, 0.473)	0.451
	PFOS × Sex (Interaction term)	0.009 (-0.447, 0.464)	0.970	0.048 (-0.415, 0.511)	0.838
A-dione (ng/mL)	PFOS	-0.038 (-0.310, 0.234)	0.782	-0.015 (-0.293, 0.264)	0.918
	Females (vs. Males)	0.038 (-0.216, 0.291)	0.769	0.006 (-0.249, 0.261)	0.963
	PFOS × Sex (Interaction term)	-0.057 (-0.399, 0.285)	0.742	-0.016 (-0.361, 0.330)	0.929
DHEA/A-dione	PFOS	0.424 (-0.021, 0.869)	0.062	0.424 (-0.039, 0.888)	0.072
	Females (vs. Males)	0.125 (-0.289, 0.539)	0.552	0.125 (-0.300, 0.549)	0.562
	PFOS × Sex (Interaction term)	0.066 (-0.493, 0.625)	0.816	0.064 (-0.511, 0.638)	0.827
T (pg/mL)	PFOS	-0.011 (-0.370, 0.347)	0.951	0.028 (-0.342, 0.398)	0.882
	Females (vs. Males)	-0.044 (-0.377, 0.290)	0.796	-0.055 (-0.395, 0.284)	0.748
	PFOS × Sex (Interaction term)	-0.081 (-0.531, 0.370)	0.724	-0.068 (-0.528, 0.391)	0.769
E ₂ (ng/mL)	PFOS	0.412 (0.126, 0.699)	0.005	0.385 (0.093, 0.677)	0.010
	Females (vs. Males)	0.201 (-0.066, 0.467)	0.139	0.170 (-0.097, 0.438)	0.210
	PFOS × Sex (Interaction term)	-0.335 (-0.695, 0.025)	0.068	-0.307 (-0.669, 0.055)	0.095
T/E ₂	PFOS	-0.423 (-0.737, -0.110)	0.008	-0.357 (-0.667, -0.048)	0.024
	Females (vs. Males)	-0.244 (-0.536, 0.047)	0.100	-0.226 (-0.509, 0.058)	0.118
	PFOS × Sex (Interaction term)	0.254 (-0.139, 0.648)	0.204	0.239 (-0.145, 0.623)	0.220
P ₄ (ng/mL)	PFOA	0.167 (-0.162, 0.496)	0.316	0.137 (-0.219, 0.494)	0.447
	Females (vs. Males)	-0.085 (-0.208, 0.038)	0.174	-0.094 (-0.221, 0.033)	0.145
	PFOA × Sex (Interaction term)	-0.145 (-0.542, 0.252)	0.472	-0.121 (-0.533, 0.290)	0.561
DHEA (ng/mL)	PFOA	-0.106 (-0.417, 0.205)	0.502	-0.120 (-0.455, 0.215)	0.479
	Females (vs. Males)	0.141 (0.024, 0.257)	0.018	0.144 (0.024, 0.263)	0.019
	PFOA × Sex (Interaction term)	0.038 (-0.337, 0.414)	0.841	-0.005 (-0.392, 0.382)	0.979
A-dione (ng/mL)	PFOA	-0.023 (-0.248, 0.202)	0.838	0.012 (-0.227, 0.251)	0.921
	Females (vs. Males)	0.002 (-0.082, 0.086)	0.967	0.005 (-0.080, 0.090)	0.904
	PFOA × Sex (Interaction term)	-0.057 (-0.329, 0.215)	0.678	-0.092 (-0.368, 0.184)	0.510
DHEA/A-dione	PFOA	-0.083 (-0.464, 0.299)	0.670	-0.132 (-0.544, 0.280)	0.527
	Females (vs. Males)	0.139 (-0.004, 0.282)	0.057	0.138 (-0.008, 0.285)	0.064
	PFOA × Sex (Interaction term)	0.095 (-0.366, 0.556)	0.683	0.087 (-0.388, 0.563)	0.717
T (pg/mL)	PFOA	-0.038 (-0.335, 0.258)	0.798	0.018 (-0.300, 0.337)	0.909
	Females (vs. Males)	-0.106 (-0.217, 0.005)	0.061	-0.101 (-0.214, 0.013)	0.081
	PFOA × Sex (Interaction term)	0.037 (-0.322, 0.395)	0.840	-0.007 (-0.375, 0.361)	0.969
E ₂ (ng/mL)	PFOA	0.122 (-0.121, 0.365)	0.323	0.086 (-0.171, 0.342)	0.510
	Females (vs. Males)	-0.020 (-0.111, 0.071)	0.669	-0.031 (-0.122, 0.060)	0.503
	PFOA × Sex (Interaction term)	-0.136 (-0.429, 0.158)	0.363	-0.140 (-0.437, 0.156)	0.350
T/E ₂	PFOA	-0.160 (-0.426, 0.105)	0.235	-0.067 (-0.338, 0.204)	0.625
	Females (vs. Males)	-0.086 (-0.186, 0.013)	0.088	-0.070 (-0.166, 0.027)	0.154
	PFOA × Sex (Interaction term)	0.172 (-0.149, 0.493)	0.290	0.133 (-0.180, 0.446)	0.402

4 Associations between maternal PFOS or PFOA levels and infant sex on sex hormone levels were
 5 evaluated using multiple linear regression models.

6 ^a Crude: Non-adjusted.

7 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third

1 trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household
2 income ($< 5/\geq 5$ million Japanese yen), parity (primipara/multipara), maternal blood sampling
3 periods (during pregnancy or after birth), and infant birth weight (grams; continuous).
4 β (95% CI) represents change (95% confidence intervals) in \log_{10} -transformed A-dione (ng/mL),
5 T (pg/mL), E_2 (ng/mL), or DHEA/A-dione levels for each 10-fold PFOS or PFOA level
6 (ng/mL).
7 PFAS-sex interaction term was defined as “ \log_{10} -transformed PFOS or PFOA levels
8 (continuous) * sex (0 = males and 1 = females)”.
9
10

1 Supplementary Table 6. Sensitivity analysis of associations between PFOS levels in maternal
 2 sera during pregnancy and female infant genotypes *CYP17A1* (rs743572) on sex hormone levels
 3 in cord sera among pregnant women and female infant pairs for which maternal blood samples
 4 were obtained before delivery

Outcome	Exposure/Genotype	Females (n = 88)			
		Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value
P ₄ (ng/mL)	PFOS (ng/mL)	-0.410 (-0.955, 0.136)	0.139	-0.442 (-0.999, 0.115)	0.118
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.014 (-0.504, 0.533)	0.956	0.049 (-0.484, 0.581)	0.856
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.165 (-0.856, 0.526)	0.636	-0.212 (-0.916, 0.493)	0.551
DHEA (ng/mL)	PFOS (ng/mL)	0.410 (-0.116, 0.936)	0.125	0.409 (-0.139, 0.957)	0.142
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.059 (-0.441, 0.560)	0.815	0.008 (-0.515, 0.532)	0.975
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	0.010 (-0.656, 0.677)	0.976	0.066 (-0.627, 0.759)	0.851
A-dione (ng/mL)	PFOS (ng/mL)	0.368 (0.020, 0.716)	0.039	0.388 (0.028, 0.748)	0.035
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.501 (0.170, 0.832)	0.003	0.484 (0.140, 0.828)	0.006
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.768 (-1.210, -0.327)	0.001	-0.742 (-1.198, -0.287)	0.002
DHEA/A-dione	PFOS (ng/mL)	0.042 (-0.587, 0.670)	0.895	0.020 (-0.633, 0.674)	0.951
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	-0.442 (-1.040, 0.156)	0.145	-0.476 (-1.100, 0.149)	0.134
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	0.779 (-0.018, 1.575)	0.055	0.808 (-0.019, 1.635)	0.055
T (pg/mL)	PFOS (ng/mL)	0.622 (0.171, 1.072)	0.007	0.639 (0.172, 1.107)	0.008
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.774 (0.345, 1.204)	0.001	0.750 (0.304, 1.197)	0.001
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-1.181 (-1.753, -0.610)	<0.001	-1.147 (-1.738, -0.556)	<0.001
E ₂ (ng/mL)	PFOS (ng/mL)	0.386 (0.031, 0.742)	0.034	0.377 (0.017, 0.738)	0.041
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.318 (-0.020, 0.657)	0.065	0.324 (-0.021, 0.668)	0.065
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.527 (-0.978, -0.076)	0.023	-0.525 (-0.981, -0.069)	0.025
T/E ₂	PFOS (ng/mL)	0.235 (-0.206, 0.677)	0.292	0.262 (-0.178, 0.703)	0.240
	<i>CYP17A1</i> (rs743572)-AG/GG (vs. AA)	0.456 (0.036, 0.876)	0.034	0.426 (0.005, 0.848)	0.047
	PFOS × <i>CYP17A1</i> (rs743572)-AG/GG (Interaction term)	-0.654 (-1.214, -0.095)	0.022	-0.622 (-1.180, -0.064)	0.029

5 Associations between maternal PFOS levels and infant genotypes on sex hormone levels were
 6 evaluated using multiple linear regression models.

7 ^a Crude: Non-adjusted.

8 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third
 9 trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household
 10 income (< 5/≥ 5 million Japanese yen), parity (primipara/multipara), infant sex (male/female; all
 11 participants), maternal blood sampling periods (during pregnancy or after birth), and infant birth
 12 weight (grams; continuous).

13 β (95% CI) represents change (95% confidence intervals) in log₁₀-transformed A-dione (ng/mL),
 14 T (pg/mL), E₂ (ng/mL), or DHEA/A-dione levels for each 10-fold PFOS level (ng/mL).

15 PFOS-*CYP17A1* (rs743572) interaction term was defined as “log₁₀-transformed PFOS levels
 16 (continuous) * genotype (0 = AA and 1 =AG/GG)”.

1 Supplementary Table 7. Sensitivity analysis of PFOS levels in maternal sera and sex steroid
 2 hormone levels in cord sera stratified by female infant genotypes *CYP17A1* (rs743572) among
 3 pregnant women and female infant pairs for which maternal blood samples were obtained before
 4 delivery

Outcome	<i>CYP17A1</i> (rs743572) Infant genotype	Exposure: PFOS (ng/mL) Females (n = 88)			
		Crude ^a β (95% CI)	p value	Adjusted ^b β (95% CI)	p value
P ₄ (ng/mL)	AA	-0.410 (-0.996, 0.177)	0.163	-0.445 (-1.046, 0.157)	0.139
	AG/GG	-0.575 (-0.995, -0.155)	0.008	-0.589 (-1.052, -0.126)	0.014
DHEA (ng/mL)	AA	0.410 (-0.100, 0.920)	0.110	0.389 (-0.129, 0.907)	0.133
	AG/GG	0.420 (-0.003, 0.843)	0.052	0.408 (-0.069, 0.885)	0.092
A-dione (ng/mL)	AA	0.368 (-0.086, 0.822)	0.108	0.396 (-0.103, 0.894)	0.113
	AG/GG	-0.401 (-0.637, -0.164)	0.001	-0.378 (-0.643, -0.112)	0.006
DHEA/A-dione	AA	0.042 (-0.505, 0.589)	0.876	-0.007 (-0.600, 0.586)	0.981
	AG/GG	0.821 (0.298, 1.343)	0.003	0.786 (0.200, 1.371)	0.010
T (pg/mL)	AA	0.622 (0.085, 1.158)	0.025	0.678 (0.074, 1.281)	0.030
	AG/GG	-0.560 (-0.889, -0.231)	0.001	-0.483 (-0.853, -0.112)	0.012
E ₂ (ng/mL)	AA	0.386 (-0.055, 0.828)	0.084	0.353 (-0.176, 0.881)	0.178
	AG/GG	-0.140 (-0.392, 0.111)	0.269	-0.137 (-0.406, 0.131)	0.309
T/E ₂	AA	0.235 (-0.230, 0.701)	0.308	0.325 (-0.156, 0.807)	0.174
	AG/GG	-0.419 (-0.763, -0.076)	0.018	-0.345 (-0.729, 0.038)	0.077

5 Associations between maternal PFOS levels and sex hormone levels were evaluated using
 6 multiple linear regression models.

7 ^a Crude: Non-adjusted.

8 ^b Adjusted: Adjusted for maternal age (years; continuous), maternal smoking during the third
 9 trimester (yes/no), maternal alcohol consumption during pregnancy (yes/no), annual household
 10 income (< 5/≥ 5 million Japanese yen), parity (primipara/multipara), infant sex (male/female; all
 11 participants), maternal blood sampling periods (during pregnancy or after birth), and infant birth
 12 weight (grams; continuous).

13 β (95% CI) represents change (95% confidence intervals) in log₁₀-transformed P₄ (ng/mL),

14 DHEA (ng/mL), A-dione (ng/mL), DHEA/A-dione, T (pg/mL), E₂ (ng/mL), or T/E₂ levels per
 15 10-fold increase in the maternal PFOS levels.

16

1 Supplementary Table 8. Association of infant genotype *CYP17A1* (rs743572) with PFOS and PFOA levels in maternal blood and sex hormone levels
 2 in cord blood

	Infant genotype <i>CYP17A1</i> (rs743572)		<i>p</i> value
	AA	AG/GG	
PFOS (ng/mL)	5.5 (3.9, 7.3)	4.8 (3.2, 6.7)	0.145
PFOA (ng/mL)	1.4 (0.9, 2.3)	1.4 (0.9, 1.8)	0.279
P ₄ (ng/mL)	236.7 (183.2, 306.0)	207.9 (170.6, 272.5)	0.068
DHEA (ng/mL)	2.1 (1.7, 3.2)	2.3 (1.9, 3.0)	0.345
A-dione (ng/mL)	0.44 (0.36, 0.61)	0.45 (0.36, 0.57)	0.644
DHEA/A-dione	5.0 (3.8, 6.1)	4.7 (3.7, 5.9)	0.780
T (pg/mL)	85.4 (57.8, 109.2)	84.2 (60.5, 111.7)	0.683
E ₂ (ng/mL)	5.4 (3.6, 7.4)	4.7 (3.3, 7.1)	0.396
T/E ₂	15.1 (11.7, 21.8)	18.0 (12.6, 22.8)	0.155

3 Median (inter-quartile range).

4 Mann-Whitney's *U*-test.

5

6

7